The	O
association	O
of	O
cytosol	O
oestrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
with	O
histological	O
features	O
of	O
breast	O
cancer	O
and	O
early	O
recurrence	O
of	O
disease	O
.	O

Two	O
hundred	O
and	O
eighty-eight	O
primary	O
breast	O
tumours	O
were	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
(	I-protein
REc	I-protein
)	I-protein
and	I-protein
progesterone	I-protein
(	I-protein
RPc	I-protein
)	I-protein
receptors	I-protein
.	O

Analysis	O
has	O
shown	O
a	O
relative	O
interdependence	O
between	O
the	O
steroid	B-protein
receptor	I-protein
status	O
of	O
primary	O
breast	O
cancer	O
and	O
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	O
,	O
lymphocytic	O
infiltration	O
and	O
tumour	O
elastosis	O
.	O

There	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	O
the	O
value	O
of	O
REc	B-protein
in	O
those	O
tumours	O
in	O
which	O
the	O
receptor	O
was	O
present	O
.	O

Cellularity	O
and	O
fibrosis	O
were	O
unrelated	O
to	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
receptor	I-protein
.	O

By	O
contrast	O
,	O
neither	O
the	O
presence	O
or	O
absence	O
nor	O
the	O
value	O
of	O
RPc	B-protein
could	O
be	O
related	O
to	O
cellularity	O
or	O
fibrosis	O
.	O

The	O
value	O
of	O
REc	B-protein
and	O
RPc	B-protein
analysis	O
as	O
an	O
indicator	O
of	O
prognosis	O
was	O
examined	O
in	O
a	O
sub-group	O
of	O
175	O
patients	O
receiving	O
no	O
additional	O
treatment	O
following	O
mastectomy	O
.	O

Overall	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
was	O
no	O
different	O
for	O
those	O
patients	O
with	O
receptors	O
compared	O
to	O
those	O
without	O
them	O
(	O
REc	B-protein
P	O
=	O
0.11	O
,	O
RPc	O
P	O
=	O
0.7	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
RFS	O
of	O
receptor	O
positive	O
and	O
negative	O
tumours	O
when	O
the	O
axillary	O
node	O
status	O
was	O
taken	O
into	O
account	O
.	O

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
47	NULL
,	NULL
629-640	NULL
The	NULL
association	NULL
of	NULL
cytosol	NULL
oestrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
with	NULL
histological	NULL
features	NULL
of	NULL
breast	NULL
cancer	NULL
and	NULL
early	NULL
recurrence	NULL
of	NULL
disease	NULL
J.M.T	NULL
.	NULL

Howat'*	NULL
,	NULL
D.M	NULL
.	NULL

Barnes	NULL
?	NULL

,	NULL
M.	NULL
Harris	NULL
's	NULL
&	NULL
R.	NULL
Swindell*	NULL
'Department	NULL
of	NULL
Surgery	NULL
,	NULL
University	NULL
Hospital	NULL
of	NULL
South	NULL
Manchester	NULL
,	NULL
Withington	NULL
;	NULL
*Department	NULL
of	NULL
Clinical	NULL
Research	NULL
,	NULL
*Department	NULL
of	NULL
Pathology	NULL
,	NULL
and	NULL
*Department	NULL
of	NULL
Medical	NULL
Statistics	NULL
,	NULL
Christie	NULL
Hospital	NULL
and	NULL
Holt	NULL
Radium	NULL
Institute	NULL
,	NULL
Manchester	NULL
.	NULL

Summary	NULL
-	NULL
Two	NULL
hundred	NULL
and	NULL
eighty-eight	NULL
primary	NULL
breast	NULL
tumours	NULL
were	NULL
examined	NULL
for	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
oestrogen	NULL
(	NULL
RE	NULL
,	NULL
)	NULL
and	NULL
progesterone	NULL
(	NULL
RP	NULL
,	NULL
)	NULL
receptors	NULL
.	NULL

Analysis	NULL
has	NULL
shown	NULL
a	NULL
relative	NULL
interdependence	NULL
between	NULL
the	NULL
steroid	NULL
receptor	NULL
status	NULL
of	NULL
primary	NULL
breast	NULL
cancer	NULL
and	NULL
other	NULL
prognostic	NULL
variables	NULL
such	NULL
as	NULL
histological	NULL
grade	NULL
,	NULL
lymphocytic	NULL
infiltration	NULL
and	NULL
tumour	NULL
elastosis	NULL
.	NULL

There	NULL
were	NULL
significant	NULL
associations	NULL
between	NULL
epithelial	NULL
cellularity	NULL
,	NULL
stromal	NULL
fibrosis	NULL
and	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
in	NULL
those	NULL
tumours	NULL
in	NULL
which	NULL
the	NULL
receptor	NULL
was	NULL
present	NULL
.	NULL

Cellularity	NULL
and	NULL
fibrosis	NULL
were	NULL
unrelated	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
oestrogen	NULL
receptor	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
neither	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
nor	NULL
the	NULL
value	NULL
of	NULL
RP	NULL
,	NULL
could	NULL
be	NULL
related	NULL
to	NULL
cellularity	NULL
or	NULL
fibrosis	NULL
.	NULL

The	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
analysis	NULL
as	NULL
an	NULL
indicator	NULL
of	NULL
prognosis	NULL
was	NULL
examined	NULL
in	NULL
a	NULL
sub-group	NULL
of	NULL
175	NULL
patients	NULL
receiving	NULL
no	NULL
additional	NULL
treatment	NULL
following	NULL
mastectomy	NULL
.	NULL

Overall	NULL
relapse-free	NULL
survival	NULL
(	NULL
RFS	NULL
)	NULL
was	NULL
no	NULL
different	NULL
for	NULL
those	NULL
patients	NULL
with	NULL
receptors	NULL
compared	NULL
to	NULL
those	NULL
without	NULL
them	NULL
(	NULL
RE	NULL
,	NULL
P=0.11	NULL
,	NULL
RP	NULL
,	NULL
P=0.7	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
RFS	NULL
of	NULL
receptor	NULL
positive	NULL
and	NULL
negative	NULL
tumours	NULL
when	NULL
the	NULL
axillary	NULL
node	NULL
status	NULL
was	NULL
taken	NULL
into	NULL
account	NULL
.	NULL

Increased	NULL
recognition	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
selective	NULL
hormone	NULL
binding	NULL
in	NULL
initiating	NULL
steroid	NULL
action	NULL
in	NULL
target	NULL
tissues	NULL
has	NULL
led	NULL
to	NULL
the	NULL
study	NULL
of	NULL
oestrogen	NULL
and	NULL
progesterone	NULL
binding	NULL
by	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Though	NULL
the	NULL
receptor	NULL
content	NULL
of	NULL
the	NULL
primary	NULL
tumour	NULL
is	NULL
reported	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
factors	NULL
such	NULL
as	NULL
tumour	NULL
site	NULL
or	NULL
size	NULL
,	NULL
age	NULL
of	NULL
patient	NULL
or	NULL
degree	NULL
of	NULL
axillary	NULL
node	NULL
involvement	NULL
(	NULL
Knight	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
it	NULL
is	NULL
not	NULL
known	NULL
to	NULL
what	NULL
degree	NULL
tumour	NULL
differentiation	NULL
is	NULL
under	NULL
endocrine	NULL
control	NULL
.	NULL

Studies	NULL
linking	NULL
receptors	NULL
and	NULL
hormone-dependent	NULL
proteins	NULL
with	NULL
morphological	NULL
and	NULL
clinical	NULL
features	NULL
may	NULL
help	NULL
clinicians	NULL
to	NULL
recognise	NULL
tumours	NULL
which	NULL
are	NULL
hormone-sensitive	NULL
.	NULL

In	NULL
early	NULL
studies	NULL
of	NULL
this	NULL
nature	NULL
there	NULL
was	NULL
no	NULL
-	NULL
consistent	NULL
-	NULL
relationship	NULL
-	NULL
between	NULL
-	NULL
specific	NULL
histopathological	NULL
features	NULL
of	NULL
the	NULL
tumour	NULL
and	NULL
either	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
Sander	NULL
,	NULL
1968	NULL
;	NULL
Korenman	NULL
&	NULL
Dukes	NULL
,	NULL
1970	NULL
;	NULL
Johansson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1970	NULL
;	NULL
Feherty	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
Wittliff	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
LeClereq	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1973	NULL
;	NULL
Terenius	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1974	NULL
;	NULL
Aspergren	NULL
&	NULL
Hakansson	NULL
,	NULL
1974	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
some	NULL
of	NULL
these	NULL
studies	NULL
numbers	NULL
were	NULL
small	NULL
and	NULL
methods	NULL
of	NULL
RE	NULL
,	NULL
analysis	NULL
and	NULL
morphological	NULL
examination	NULL
were	NULL
inconsistent	NULL
.	NULL

More	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
RE	NULL
,	NULL
may	NULL
be	NULL
closely	NULL
related	NULL
to	NULL
tumour	NULL
grade	NULL
(	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979b	NULL
;	NULL
Correspondence	NULL
:	NULL
-	NULL
J.M.T	NULL
.	NULL

Howat	NULL
.	NULL

*Present	NULL
-	NULL
address	NULL
:	NULL
Department	NULL
-	NULL
of	NULL
-	NULL
Surgery	NULL
-	NULL
North	NULL
Manchester	NULL
General	NULL
Hospital	NULL
,	NULL
Manchester	NULL
,	NULL
M8	NULL
6RH	NULL
.	NULL

Received	NULL
3	NULL
November	NULL
1982	NULL
;	NULL
accepted	NULL
15	NULL
February	NULL
1983	NULL
.	NULL

Rasmussen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
;	NULL
Thoresen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
,	NULL
to	NULL
the	NULL
histological	NULL
type	NULL
and	NULL
degree	NULL
of	NULL
lymphocytic	NULL
infiltration	NULL
of	NULL
primary	NULL
tumour	NULL
(	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
and	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
elastosis	NULL
in	NULL
the	NULL
tumour	NULL
stroma	NULL
(	NULL
Masters	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1976	NULL
)	NULL
.	NULL

Similar	NULL
links	NULL
have	NULL
been	NULL
recognised	NULL
between	NULL
the	NULL
progesterone	NULL
receptor	NULL
(	NULL
RP	NULL
,	NULL
)	NULL
and	NULL
histological	NULL
grade	NULL
and	NULL
elastosis	NULL
(	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979b	NULL
;	NULL
Rolland	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
,	NULL
but	NULL
a	NULL
relationship	NULL
between	NULL
RP	NULL
,	NULL
and	NULL
other	NULL
aspects	NULL
of	NULL
tumour	NULL
morphology	NULL
has	NULL
not	NULL
been	NULL
reported	NULL
.	NULL

Most	NULL
investigators	NULL
who	NULL
have	NULL
studied	NULL
the	NULL
relationship	NULL
between	NULL
RE	NULL
,	NULL
and	NULL
freedom	NULL
from	NULL
recurrence	NULL
and	NULL
survival	NULL
,	NULL
have	NULL
suggested	NULL
that	NULL
an	NULL
earlier	NULL
recurrence	NULL
and	NULL
shorter	NULL
survival	NULL
may	NULL
be	NULL
expected	NULL
in	NULL
those	NULL
patients	NULL
who	NULL
lack	NULL
RE	NULL
,	NULL
in	NULL
their	NULL
primary	NULL
tumour	NULL
,	NULL
although	NULL
data	NULL
vary	NULL
as	NULL
to	NULL
which	NULL
patients	NULL
obtain	NULL
the	NULL
greatest	NULL
benefit	NULL
(	NULL
Knight	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
;	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Bishop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Cooke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Allegra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Forrest	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Westerberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Croton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

As	NULL
the	NULL
RE	NULL
,	NULL
is	NULL
said	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
other	NULL
prognostic	NULL
-	NULL
variables	NULL
in	NULL
breast	NULL
cancer	NULL
,	NULL
the	NULL
measurement	NULL
of	NULL
this	NULL
receptor	NULL
has	NULL
been	NULL
advocated	NULL
as	NULL
a	NULL
means	NULL
of	NULL
selecting	NULL
patients	NULL
likely	NULL
to	NULL
benefit	NULL
most	NULL
from	NULL
systemic	NULL
adjuvant	NULL
therapy	NULL
(	NULL
Cooke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
Hilf	NULL
and	NULL
his	NULL
colleagues	NULL
(	NULL
1980	NULL
)	NULL
were	NULL
unable	NULL
to	NULL
confirm	NULL
that	NULL
RE	NULL
,	NULL
has	NULL
any	NULL
beneficial	NULL
effect	NULL
on	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

Similar	NULL
studies	NULL
which	NULL
link	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RP	NULL
,	NULL
to	NULL
relapse-free	NULL
survival	NULL
(	NULL
RFS	NULL
)	NULL
,	NULL
have	NULL
also	NULL
produced	NULL
conflicting	NULL
results	NULL
(	NULL
Pichon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Allegra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Kinne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
and	NULL
the	NULL
role	NULL
©	NULL
The	NULL
Macmillan	NULL
Press	NULL
Ltd.	NULL
,	NULL
1983	NULL
630	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
et	NULL
al	NULL
.	NULL

of	NULL
this	NULL
receptor	NULL
as	NULL
a	NULL
prognostic	NULL
factor	NULL
in	NULL
breast	NULL
cancer	NULL
remains	NULL
uncertain	NULL
.	NULL

The	NULL
objectives	NULL
of	NULL
this	NULL
single	NULL
centre	NULL
study	NULL
were	NULL
twofold	NULL
:	NULL
to	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
is	NULL
a	NULL
reflection	NULL
of	NULL
certain	NULL
morphological	NULL
features	NULL
of	NULL
the	NULL
tumour	NULL
,	NULL
some	NULL
of	NULL
which	NULL
are	NULL
of	NULL
prognostic	NULL
significance	NULL
in	NULL
their	NULL
own	NULL
right	NULL
and	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
as	NULL
indicators	NULL
of	NULL
early	NULL
recurrence	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Oestrogen	NULL
and	NULL
progesterone	NULL
receptor	NULL
assay	NULL
Samples	NULL
of	NULL
histologically	NULL
proven	NULL
primary	NULL
tumours	NULL
from	NULL
women	NULL
with	NULL
breast	NULL
cancer	NULL
were	NULL
studied	NULL
.	NULL

Portions	NULL
for	NULL
oestrogen	NULL
(	NULL
RE	NULL
,	NULL
)	NULL
and	NULL
progesterone	NULL
(	NULL
RP	NULL
,	NULL
)	NULL
receptor	NULL
measurement	NULL
were	NULL
selected	NULL
at	NULL
the	NULL
time	NULL
of	NULL
surgery	NULL
by	NULL
the	NULL
pathologist	NULL
who	NULL
received	NULL
tissue	NULL
for	NULL
frozen	NULL
section	NULL
.	NULL

They	NULL
were	NULL
stored	NULL
in	NULL
liquid	NULL
nitrogen	NULL
until	NULL
required	NULL
for	NULL
analysis	NULL
,	NULL
and	NULL
then	NULL
homogenised	NULL
and	NULL
centrifuged	NULL
.	NULL

The	NULL
receptor	NULL
content	NULL
of	NULL
the	NULL
cytosol	NULL
was	NULL
measured	NULL
by	NULL
incubation	NULL
with	NULL
either	NULL
tritiated	NULL
oestradiol	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
diethyl-stilboestrol	NULL
as	NULL
a	NULL
competitor	NULL
for	NULL
specific	NULL
oestrogen	NULL
receptor	NULL
sites	NULL
,	NULL
or	NULL
tritiated	NULL
R5020	NULL
and	NULL
radio-inert	NULL
R5020	NULL
,	NULL
a	NULL
synthetic	NULL
progestin	NULL
,	NULL
for	NULL
specific	NULL
progesterone	NULL
receptor	NULL
sites	NULL
Non-receptor	NULL
bound	NULL
[	NULL
*H	NULL
]	NULL
}	NULL
-hormone	NULL
was	NULL
separated	NULL
from	NULL
hormone	NULL
bound	NULL
to	NULL
receptors	NULL
by	NULL
adsorption	NULL
on	NULL
to	NULL
Dextran-coated	NULL
charcoal	NULL
(	NULL
DCC	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
receptor-bound	NULL
radio-labelled	NULL
-	NULL
hormone	NULL
-	NULL
remaining	NULL
in	NULL
-	NULL
the	NULL
supernatant	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
and	NULL
the	NULL
data	NULL
analysed	NULL
according	NULL
to	NULL
Scatchard	NULL
(	NULL
1949	NULL
)	NULL
.	NULL

Values	NULL
>	NULL
5fMmg~	NULL
'	NULL
for	NULL
RE	NULL
,	NULL
and	NULL
>	NULL
15fMmg~	NULL
'	NULL
for	NULL
RP	NULL
,	NULL
of	NULL
cytosol	NULL
protein	NULL
were	NULL
regarded	NULL
as	NULL
positive	NULL
(	NULL
Barnes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
;	NULL
Skinner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
.	NULL

Negative	NULL
results	NULL
from	NULL
tumours	NULL
where	NULL
the	NULL
cytosol	NULL
protein	NULL
was	NULL
<	NULL
0.7mgmIl~	NULL
'	NULL
were	NULL
not	NULL
accepted	NULL
as	NULL
valid	NULL
and	NULL
were	NULL
excluded	NULL
from	NULL
the	NULL
study	NULL
.	NULL

Histology	NULL
The	NULL
pathological	NULL
features	NULL
of	NULL
288	NULL
unselected	NULL
primary	NULL
malignant	NULL
-	NULL
breast	NULL
tumours	NULL
-	NULL
were	NULL
-	NULL
reviewed	NULL
retrospectively	NULL
by	NULL
one	NULL
pathologist	NULL
who	NULL
was	NULL
unaware	NULL
of	NULL
the	NULL
receptor	NULL
status	NULL
.	NULL

His	NULL
observations	NULL
were	NULL
based	NULL
on	NULL
the	NULL
examination	NULL
of	NULL
routine	NULL
paraffin	NULL
wax	NULL
embedded	NULL
sections	NULL
stained	NULL
with	NULL
haematoxylin	NULL
and	NULL
eosin	NULL
and	NULL
sections	NULL
stained	NULL
for	NULL
elastic	NULL
tissue	NULL
with	NULL
Miller	NULL
's	NULL
Victoria	NULL
blue	NULL
and	NULL
Van	NULL
Geison	NULL
stain	NULL
.	NULL

The	NULL
following	NULL
pathological	NULL
observations	NULL
were	NULL
made	NULL
:	NULL
the	NULL
maximum	NULL
diameter	NULL
,	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
margin	NULL
(	NULL
circumscribed	NULL
or	NULL
stellate	NULL
)	NULL
,	NULL
and	NULL
the	NULL
histological	NULL
type	NULL
of	NULL
the	NULL
primary	NULL
tumour	NULL
.	NULL

The	NULL
grade	NULL
of	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
was	NULL
assessed	NULL
on	NULL
a	NULL
scale	NULL
of	NULL
1	NULL
(	NULL
well-differentiated	NULL
)	NULL
to	NULL
3	NULL
(	NULL
poorly-differentiated	NULL
)	NULL
taking	NULL
into	NULL
account	NULL
tubular	NULL
differentiation	NULL
,	NULL
nuclear	NULL
pleomorphism	NULL
and	NULL
mitotic	NULL
activity	NULL
according	NULL
to	NULL
the	NULL
method	NULL
recommended	NULL
by	NULL
Scarff	NULL
&	NULL
Torloni	NULL
(	NULL
1968	NULL
)	NULL
which	NULL
is	NULL
essentially	NULL
that	NULL
of	NULL
Bloom	NULL
&	NULL
Richardson	NULL
(	NULL
1957	NULL
)	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
lymphoid	NULL
reaction	NULL
in	NULL
and	NULL
around	NULL
the	NULL
primary	NULL
tumour	NULL
was	NULL
evaluated	NULL
on	NULL
a	NULL
scale	NULL
of	NULL
1	NULL
(	NULL
slight	NULL
or	NULL
none	NULL
)	NULL
to	NULL
3	NULL
(	NULL
marked	NULL
)	NULL
,	NULL
and	NULL
the	NULL
epithelial	NULL
cellularity	NULL
of	NULL
the	NULL
middle	NULL
and	NULL
the	NULL
edge	NULL
of	NULL
the	NULL
tumour	NULL
,	NULL
the	NULL
stromal	NULL
reaction	NULL
or	NULL
fibrosis	NULL
within	NULL
the	NULL
tumour	NULL
and	NULL
the	NULL
degree	NULL
of	NULL
elastic	NULL
tissue	NULL
formation	NULL
within	NULL
the	NULL
stroma	NULL
were	NULL
similarly	NULL
assessed	NULL
.	NULL

This	NULL
is	NULL
a	NULL
semi-quantitative	NULL
visual	NULL
assessment	NULL
based	NULL
on	NULL
the	NULL
experience	NULL
of	NULL
the	NULL
pathologist	NULL
.	NULL

Assessment	NULL
of	NULL
recurrence	NULL
The	NULL
relationship	NULL
of	NULL
the	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
status	NULL
to	NULL
the	NULL
development	NULL
of	NULL
early	NULL
recurrence	NULL
of	NULL
the	NULL
disease	NULL
was	NULL
studied	NULL
in	NULL
a	NULL
subgroup	NULL
of	NULL
175	NULL
patients	NULL
with	NULL
operable	NULL
disease	NULL
(	NULL
T	NULL
,	NULL
-	NULL
;	NULL
M	NULL
,	NULL
)	NULL
.	NULL

Each	NULL
had	NULL
a	NULL
Patey	NULL
modified	NULL
radical	NULL
mastectomy	NULL
.	NULL

After	NULL
histological	NULL
examination	NULL
of	NULL
the	NULL
axillary	NULL
nodes	NULL
,	NULL
the	NULL
patients	NULL
were	NULL
classified	NULL
into	NULL
three	NULL
groups	NULL
:	NULL
those	NULL
with	NULL
no	NULL
nodes	NULL
containing	NULL
tumour	NULL
;	NULL
those	NULL
with	NULL
1-3	NULL
nodes	NULL
containing	NULL
tumour	NULL
;	NULL
and	NULL
patients	NULL
with	NULL
4	NULL
or	NULL
more	NULL
nodes	NULL
containing	NULL
tumour	NULL
.	NULL

Patients	NULL
with	NULL
bilateral	NULL
tumours	NULL
,	NULL
or	NULL
distant	NULL
metastases	NULL
and	NULL
those	NULL
receiving	NULL
adjuvant	NULL
hormone	NULL
or	NULL
cytotoxic	NULL
therapy	NULL
were	NULL
excluded	NULL
from	NULL
this	NULL
part	NULL
of	NULL
the	NULL
study	NULL
.	NULL

The	NULL
patients	NULL
were	NULL
examined	NULL
one	NULL
month	NULL
after	NULL
operation	NULL
,	NULL
then	NULL
every	NULL
6	NULL
weeks	NULL
for	NULL
2	NULL
years	NULL
and	NULL
thereafter	NULL
annually	NULL
.	NULL

Local	NULL
recurrence	NULL
and	NULL
nodal	NULL
disease	NULL
was	NULL
confirmed	NULL
where	NULL
possible	NULL
by	NULL
biopsy	NULL
while	NULL
distant	NULL
bone	NULL
and	NULL
visceral	NULL
metastases	NULL
were	NULL
diagnosed	NULL
on	NULL
unequivocal	NULL
radiological	NULL
evidence	NULL
.	NULL

Statistical	NULL
methods	NULL
The	NULL
Chi-squared	NULL
test	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
association	NULL
between	NULL
histological	NULL
features	NULL
and	NULL
receptor	NULL
status	NULL
in	NULL
rxc	NULL
contingency	NULL
tables	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
content	NULL
and	NULL
degrees	NULL
-	NULL
of	NULL
-	NULL
cellularity	NULL
,	NULL
-	NULL
fibrosis	NULL
,	NULL
-	NULL
lymphocytic	NULL
infiltration	NULL
,	NULL
elastosis	NULL
and	NULL
histological	NULL
grade	NULL
was	NULL
examined	NULL
by	NULL
means	NULL
of	NULL
the	NULL
Kruskal	NULL
Wallis	NULL
non-parametric	NULL
one-way	NULL
Analysis	NULL
of	NULL
Variance	NULL
(	NULL
ANOVA	NULL
)	NULL
.	NULL

For	NULL
studies	NULL
of	NULL
RFS	NULL
time-based	NULL
curves	NULL
were	NULL
computed	NULL
by	NULL
actuarial	NULL
methods	NULL
and	NULL
compared	NULL
by	NULL
the	NULL
log-rank	NULL
test	NULL
(	NULL
Peto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
.	NULL

Results	NULL
Receptor	NULL
status	NULL
and	NULL
age	NULL
The	NULL
subgroups	NULL
of	NULL
patients	NULL
analysed	NULL
in	NULL
relation	NULL
to	NULL
histology	NULL
(	NULL
288	NULL
)	NULL
or	NULL
recurrence	NULL
of	NULL
disease	NULL
(	NULL
175	NULL
)	NULL
were	NULL
shown	NULL
statistically	NULL
to	NULL
be	NULL
similar	NULL
in	NULL
composition	NULL
in	NULL
terms	NULL
of	NULL
age	NULL
,	NULL
menopausal	NULL
status	NULL
,	NULL
and	NULL
frequency	NULL
of	NULL
receptor-positive	NULL
tumours	NULL
,	NULL
to	NULL
an	NULL
overall	NULL
group	NULL
of	NULL
HORMONE	NULL
RECEPTORS	NULL
IN	NULL
EARLY	NULL
BREAST	NULL
CANCER	NULL
631	NULL
523	NULL
consecutive	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
studied	NULL
in	NULL
a	NULL
4-year	NULL
period	NULL
,	NULL
but	NULL
in	NULL
whom	NULL
complete	NULL
histological	NULL
or	NULL
follow-up	NULL
data	NULL
was	NULL
not	NULL
available	NULL
.	NULL

Sixty	NULL
per	NULL
cent	NULL
of	NULL
the	NULL
patients	NULL
had	NULL
tumours	NULL
containing	NULL
RE	NULL
,	NULL
and	NULL
40	NULL
%	NULL
,	NULL
RP	NULL
,	NULL
.	NULL

Fifty-three	NULL
per	NULL
cent	NULL
of	NULL
premenopausal	NULL
and	NULL
62	NULL
%	NULL
,	NULL
of	NULL
postmenopausal	NULL
patients	NULL
possessed	NULL
RE	NULL
,	NULL
.	NULL

Absolute	NULL
values	NULL
of	NULL
RE	NULL
,	NULL
showed	NULL
a	NULL
statistically	NULL
significant	NULL
association	NULL
with	NULL
age	NULL
,	NULL
being	NULL
higher	NULL
in	NULL
older	NULL
women	NULL
and	NULL
confirming	NULL
a	NULL
previous	NULL
observation	NULL
from	NULL
our	NULL
laboratory	NULL
(	NULL
Skinner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
.	NULL

For	NULL
RP	NULL
,	NULL
the	NULL
proportions	NULL
of	NULL
receptor-positive	NULL
premenopausal	NULL
(	NULL
43	NULL
%	NULL
)	NULL
and	NULL
postmenopausal	NULL
(	NULL
38	NULL
%	NULL
)	NULL
patients	NULL
were	NULL
similar	NULL
and	NULL
age	NULL
had	NULL
.	NULL

no	NULL
influence	NULL
on	NULL
the	NULL
value	NULL
of	NULL
RP	NULL
,	NULL
.	NULL

Receptor	NULL
status	NULL
and	NULL
pathological	NULL
parameters	NULL
The	NULL
morphological	NULL
and	NULL
histological	NULL
features	NULL
of	NULL
288	NULL
primary	NULL
tumours	NULL
were	NULL
studied	NULL
in	NULL
relation	NULL
to	NULL
both	NULL
the	NULL
receptor	NULL
status	NULL
,	NULL
and	NULL
in	NULL
-	NULL
receptor-positive	NULL
tumours	NULL
,	NULL
to	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
.	NULL

There	NULL
was	NULL
no	NULL
relationship	NULL
between	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
and	NULL
either	NULL
the	NULL
diameter	NULL
of	NULL
the	NULL
tumour	NULL
or	NULL
whether	NULL
the	NULL
margins	NULL
were	NULL
circumscribed	NULL
or	NULL
infiltrative	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
receptor	NULL
status	NULL
and	NULL
histological	NULL
type	NULL
of	NULL
tumour	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

All	NULL
of	NULL
the	NULL
tubular	NULL
carcinomas	NULL
contained	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
.	NULL

,	NULL
and	NULL
70	NULL
%	NULL
,	NULL
of	NULL
the	NULL
infiltrating	NULL
lobular	NULL
carcinomas	NULL
contained	NULL
RE	NULL
,	NULL
.	NULL

However	NULL
,	NULL
the	NULL
numbers	NULL
of	NULL
some	NULL
types	NULL
of	NULL
tumour	NULL
were	NULL
too	NULL
small	NULL
to	NULL
permit	NULL
statistical	NULL
evaluation	NULL
.	NULL

1004	NULL
2=0.0004	NULL
R	NULL
so-	NULL
]	NULL
-	NULL
UAEcve	NULL
33/44	NULL
pays	NULL
6	NULL
50/77	NULL
_	NULL
607	NULL
2	NULL
LJ	NULL
el	NULL
&	NULL
C	NULL
LJ	NULL
*	NULL
40	NULL
27/77	NULL
12/36	NULL
11/44	NULL
20	NULL
o	NULL
1	NULL
2	NULL
3	NULL
Figure	NULL
1	NULL
Table	NULL
1	NULL
Relationship	NULL
of	NULL
histological	NULL
type	NULL
of	NULL
primary	NULL
tumour	NULL
to	NULL
oestrogen	NULL
and	NULL
progesterone	NULL
receptor	NULL
status	NULL
RE	NULL
,	NULL
RP	NULL
,	NULL
No	NULL
.	NULL

No	NULL
.	NULL

Histological	NULL
type	NULL
positive	NULL
(	NULL
C	NULL
,	NULL
)	NULL
-	NULL
positive	NULL
C	NULL
,	NULL
,	NULL
)	NULL
Intraduct	NULL
59	NULL
(	NULL
55	NULL
)	NULL
39	NULL
(	NULL
33	NULL
)	NULL
Infiltrating	NULL
duct*	NULL
148/248	NULL
(	NULL
60	NULL
)	NULL
100/233	NULL
(	NULL
43	NULL
)	NULL
Infiltrating	NULL
papillary	NULL
1/1	NULL
_	NULL
(	NULL
100	NULL
)	NULL
__	NULL
--	NULL
--	NULL
Mucoid	NULL
5/8	NULL
(	NULL
63	NULL
)	NULL
1/8	NULL
(	NULL
13	NULL
)	NULL
Medullary	NULL
0.3	NULL
(	NULL
0	NULL
)	NULL
0/3	NULL
(	NULL
0	NULL
)	NULL
Infiltrating	NULL
lobular	NULL
7/10	NULL
(	NULL
70	NULL
)	NULL
4,10	NULL
(	NULL
40	NULL
)	NULL
Tubular	NULL
77	NULL
(	NULL
100	NULL
)	NULL
5/5	NULL
(	NULL
100	NULL
)	NULL
Sarcoma	NULL
0	NULL
;	NULL
2	NULL
(	NULL
0	NULL
)	NULL
_	NULL
0,2	NULL
(	NULL
0	NULL
)	NULL
*All	NULL
grades	NULL
.	NULL

Histological	NULL
grade	NULL
RE	NULL
,	NULL
was	NULL
measured	NULL
in	NULL
157	NULL
and	NULL
RP	NULL
,	NULL
in	NULL
142	NULL
infiltrating	NULL
duct	NULL
carcinomas	NULL
in	NULL
which	NULL
grade	NULL
was	NULL
assessed	NULL
.	NULL

There	NULL
was	NULL
a	NULL
highly	NULL
significant	NULL
association	NULL
between	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
both	NULL
types	NULL
of	NULL
receptor	NULL
and	NULL
the	NULL
histological	NULL
grade	NULL
(	NULL
RE	NULL
,	NULL
vs.	NULL
grade	NULL
P=0.0004	NULL
:	NULL
RE	NULL
,	NULL
vs.	NULL
grade	NULL
P=0.0001	NULL
)	NULL
.	NULL

RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
occurred	NULL
most	NULL
frequently	NULL
in	NULL
-	NULL
grade	NULL
1	NULL
(	NULL
well-differentiated	NULL
)	NULL
-	NULL
tumours	NULL
whereas	NULL
-	NULL
there	NULL
-	NULL
were	NULL
relatively	NULL
few	NULL
receptor-positive	NULL
tumours	NULL
in	NULL
grade	NULL
III	NULL
(	NULL
poorly-differentiated	NULL
)	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

In	NULL
receptor-positive	NULL
tumours	NULL
there	NULL
was	NULL
no	NULL
association	NULL
between	NULL
grade	NULL
and	NULL
value	NULL
of	NULL
either	NULL
RE	NULL
,	NULL
(	NULL
P=0.6	NULL
)	NULL
or	NULL
RP	NULL
,	NULL
P=0.0001	NULL
-	NULL
RP	NULL
-ve	NULL
29/34	NULL
[	NULL
Q	NULL
ar+ve	NULL
25739	NULL
|	NULL
agree	NULL
14/39	NULL
26/69	NULL
5/34	NULL
1	NULL
2	NULL
3	NULL
GRADES	NULL
Relationship	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
to	NULL
grade	NULL
of	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
.	NULL

632	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
er	NULL
al	NULL
.	NULL

(	NULL
P=0.8	NULL
)	NULL
.	NULL

Specific	NULL
types	NULL
of	NULL
tumours	NULL
,	NULL
e.g	NULL
.	NULL

lobular	NULL
,	NULL
medullary	NULL
and	NULL
tubular	NULL
,	NULL
were	NULL
not	NULL
graded	NULL
and	NULL
were	NULL
excluded	NULL
from	NULL
this	NULL
section	NULL
.	NULL

Cellularity	NULL
and	NULL
fibrosis	NULL
In	NULL
those	NULL
tumours	NULL
in	NULL
which	NULL
receptors	NULL
were	NULL
found	NULL
there	NULL
was	NULL
a	NULL
-	NULL
significant	NULL
association	NULL
-	NULL
between	NULL
cellularity	NULL
,	NULL
both	NULL
at	NULL
the	NULL
centre	NULL
and	NULL
at	NULL
the	NULL
edge	NULL
of	NULL
the	NULL
tumour	NULL
,	NULL
and	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
although	NULL
cellularity	NULL
was	NULL
unrelated	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
RE	NULL
,	NULL
,	NULL
vs.	NULL
cellularity	NULL
edge	NULL
,	NULL
P=0.7	NULL
;	NULL
centre	NULL
,	NULL
P=0.1	NULL
)	NULL
.	NULL

Tumour	NULL
cellularity	NULL
was	NULL
not	NULL
related	NULL
to	NULL
either	NULL
the	NULL
value	NULL
of	NULL
RP	NULL
,	NULL
(	NULL
edge	NULL
,	NULL
P=0.2	NULL
;	NULL
centre	NULL
,	NULL
P	NULL
=0.3	NULL
)	NULL
,	NULL
or	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
this	NULL
receptor	NULL
(	NULL
RP	NULL
,	NULL
vs.	NULL
cellularity	NULL
centre	NULL
,	NULL
P=0.5	NULL
;	NULL
edge	NULL
,	NULL
P=0.8	NULL
)	NULL
.	NULL

In	NULL
RE	NULL
,	NULL
.-positive	NULL
tumours	NULL
there	NULL
was	NULL
an	NULL
-	NULL
inverse	NULL
association	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
stromal	NULL
fibrosis	NULL
and	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
,	NULL
those	NULL
tumours	NULL
with	NULL
most	NULL
fibrosis	NULL
containing	NULL
lowest	NULL
values	NULL
of	NULL
receptor	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
although	NULL
there	NULL
was	NULL
no	NULL
association	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
fibrosis	NULL
and	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
P=0.2	NULL
)	NULL
.	NULL

Fibrosis	NULL
was	NULL
not	NULL
related	NULL
to	NULL
either	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
value	NULL
of	NULL
RP	NULL
,	NULL
(	NULL
P=0.2	NULL
,	NULL
P=0.5	NULL
)	NULL
.	NULL

Elastosis	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
,	NULL
were	NULL
found	NULL
in	NULL
72	NULL
%	NULL
(	NULL
32/44	NULL
)	NULL
and	NULL
59	NULL
%	NULL
(	NULL
23/39	NULL
)	NULL
respectively	NULL
of	NULL
those	NULL
tumours	NULL
with	NULL
a	NULL
marked	NULL
degree	NULL
of	NULL
elastic	NULL
tissue	NULL
within	NULL
the	NULL
stroma	NULL
compared	NULL
with	NULL
67	NULL
%	NULL
(	NULL
37/55	NULL
)	NULL
and	NULL
36	NULL
%	NULL
(	NULL
17/47	NULL
)	NULL
of	NULL
tumours	NULL
with	NULL
moderate	NULL
elastosis	NULL
and	NULL
49	NULL
%	NULL
(	NULL
36/73	NULL
)	NULL
and	NULL
26	NULL
%	NULL
,	NULL
(	NULL
18/68	NULL
)	NULL
800	NULL
P	NULL
<	NULL
0.0001	NULL
600	NULL
400	NULL
7	NULL
RE	NULL
,	NULL
VALUE	NULL
(	NULL
fM	NULL
mg~	NULL
'	NULL
protein	NULL
)	NULL
200	NULL
-	NULL
f	NULL
emees	NULL
MILD	NULL
MODERATE	NULL
MARKED	NULL
CELLULARITY	NULL
Figure	NULL
2	NULL
RE	NULL
,	NULL
values	NULL
related	NULL
to	NULL
cellularity	NULL
assessed	NULL
at	NULL
the	NULL
tumour	NULL
edge	NULL
.	NULL

Median	NULL
value	NULL
and	NULL
upper	NULL
and	NULL
lower	NULL
quartiles	NULL
shown	NULL
.	NULL

of	NULL
those	NULL
with	NULL
none	NULL
.	NULL

For	NULL
both	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
these	NULL
were	NULL
statistically	NULL
significant	NULL
associations	NULL
(	NULL
RE	NULL
,	NULL
vs.	NULL
elastosis	NULL
,	NULL
P=0.02	NULL
;	NULL
RP	NULL
,	NULL
vs.	NULL
elastosis	NULL
,	NULL
P=0.004	NULL
)	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
association	NULL
between	NULL
degree	NULL
of	NULL
elastosis	NULL
and	NULL
value	NULL
of	NULL
either	NULL
RE	NULL
,	NULL
or	NULL
RP	NULL
,	NULL
(	NULL
P=0.4	NULL
)	NULL
.	NULL

P=0.02	NULL
P=0.004	NULL
100	NULL
7	NULL
.	NULL

RE	NULL
-ve	NULL
.	NULL

RP_-ve	NULL
D	NULL
RE	NULL
+ve	NULL
D	NULL
RP	NULL
+ve	NULL
80	NULL
32/44	NULL
50/68	NULL
37/55	NULL
30/47	NULL
60	NULL
-	NULL
23/39	NULL
3773	NULL
35/73	NULL
16/39	NULL
40	NULL
-	NULL
17/47	NULL
18/55	NULL
12/44	NULL
18/68	NULL
20	NULL
0	NULL
NONE	NULL
MODERATE	NULL
MARKED	NULL
NONE	NULL
MODERATE	NULL
MARKED	NULL
ELASTOSIS	NULL
Figure	NULL
3	NULL
-	NULL
Relationship	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
to	NULL
the	NULL
degree	NULL
of	NULL
elastic	NULL
tissue	NULL
formation	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

HORMONE	NULL
RECEPTORS	NULL
IN	NULL
EARLY	NULL
BREAST	NULL
CANCER	NULL
6	NULL
Lymphocytic	NULL
infiltration	NULL
Only	NULL
30	NULL
%	NULL
,	NULL
(	NULL
9/30	NULL
)	NULL
of	NULL
tumours	NULL
with	NULL
a	NULL
marked	NULL
lymphocytic	NULL
infiltrate	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
RE	NULL
,	NULL
in	NULL
contrast	NULL
with	NULL
73°	NULL
,	NULL
(	NULL
69/94	NULL
)	NULL
of	NULL
tumours	NULL
with	NULL
no	NULL
lymphocytic	NULL
reaction	NULL
(	NULL
P=0.0001	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
inverse	NULL
association	NULL
was	NULL
found	NULL
for	NULL
RP	NULL
,	NULL
.	NULL

Ninety-three	NULL
per	NULL
cent	NULL
of	NULL
tumours	NULL
with	NULL
a	NULL
marked	NULL
lymphocytic	NULL
reaction	NULL
were	NULL
RP	NULL
,	NULL
negative	NULL
(	NULL
P=0.0004	NULL
)	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
association	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
lymphocytic	NULL
infiltration	NULL
and	NULL
the	NULL
value	NULL
of	NULL
either	NULL
receptor	NULL
(	NULL
RE	NULL
,	NULL
,	NULL
P=0.9	NULL
;	NULL
RP	NULL
,	NULL
,	NULL
P=0.3	NULL
)	NULL
.	NULL

Inter-relationships	NULL
of	NULL
grade	NULL
,	NULL
lymphocytic	NULL
infiltration	NULL
und	NULL
elastosis	NULL
There	NULL
was	NULL
a	NULL
highly	NULL
significant	NULL
association	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
-	NULL
lymphocytic	NULL
-	NULL
infiltration	NULL
_	NULL
and	NULL
histological	NULL
grade	NULL
of	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
(	NULL
Table	NULL
H	NULL
)	NULL
.	NULL

High	NULL
grade	NULL
tumours	NULL
contained	NULL
the	NULL
most	NULL
marked	NULL
lymphoid	NULL
reaction	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

Table	NULL
III	NULL
summarizes	NULL
the	NULL
inverse	NULL
association	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
elastosis	NULL
and	NULL
histological	NULL
grade	NULL
,	NULL
elastosis	NULL
being	NULL
most	NULL
marked	NULL
in	NULL
grade	NULL
1	NULL
tumours	NULL
(	NULL
P	NULL
=0.0001	NULL
)	NULL
.	NULL

ROCK/NU	NULL
``	NULL
status	NULL
and	NULL
node	NULL
metastases	NULL
There	NULL
was	NULL
no	NULL
association	NULL
between	NULL
the	NULL
receptor	NULL
status	NULL
of	NULL
the	NULL
primary	NULL
tumour	NULL
and	NULL
the	NULL
number	NULL
of	NULL
axillary	NULL
lymph	NULL
nodes	NULL
containing	NULL
metastases	NULL
(	NULL
RE	NULL
,	NULL
rs	NULL
.	NULL

nodes	NULL
,	NULL
P=0.3	NULL
;	NULL
RP	NULL
,	NULL
vs.	NULL
nodes	NULL
,	NULL
P=0.7	NULL
)	NULL
The	NULL
histological	NULL
findings	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
IV	NULL
.	NULL

10041	NULL
P=0.0001	NULL
.	NULL

RE	NULL
-ve	NULL
so-	NULL
]	NULL
-	NULL
UAE	NULL
,	NULL
e	NULL
69/94	NULL
21/30	NULL
_	NULL
60-	NULL
34/59	NULL
2	NULL
LL	NULL
O	NULL
CC	NULL
w	NULL
25/59	NULL
40	NULL
9/30	NULL
64/94	NULL
20	NULL
-o-	NULL
MODERATE	NULL
MARKED	NULL
Po	NULL
ge	NULL
Table	NULL
II	NULL
Frequency	NULL
of	NULL
concurrence	NULL
of	NULL
each	NULL
degree	NULL
_	NULL
of	NULL
-	NULL
lymphocytic	NULL
-	NULL
infiltration	NULL
_	NULL
and	NULL
histological	NULL
grade	NULL
in	NULL
183	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
Lymphocytic	NULL
infiltration	NULL
None	NULL
Moderate	NULL
Marked	NULL
Grade	NULL
I	NULL
(	NULL
n=49	NULL
)	NULL
34	NULL
14	NULL
1	NULL
Grade	NULL
II	NULL
(	NULL
n=94	NULL
)	NULL
52	NULL
29	NULL
13	NULL
Grade	NULL
III	NULL
(	NULL
n=	NULL
40	NULL
)	NULL
4	NULL
20	NULL
16	NULL
(	NULL
P	NULL
=	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

Table	NULL
III	NULL
Frequency	NULL
of	NULL
concurrence	NULL
of	NULL
each	NULL
degree	NULL
of	NULL
elastosis	NULL
and	NULL
histological	NULL
grade	NULL
in	NULL
172	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
Elastosis	NULL
None	NULL
-	NULL
Present	NULL
_	NULL
Marked	NULL
Grade	NULL
I	NULL
(	NULL
n=48	NULL
)	NULL
14	NULL
12	NULL
22	NULL
Grade	NULL
II	NULL
(	NULL
n=85	NULL
)	NULL
30	NULL
35	NULL
20	NULL
Grade	NULL
III	NULL
(	NULL
n=	NULL
39	NULL
)	NULL
25	NULL
12	NULL
2	NULL
(	NULL
P	NULL
=0.0001	NULL
)	NULL
.	NULL

Receptors	NULL
and	NULL
recurrence	NULL
rates	NULL
When	NULL
the	NULL
follow-up	NULL
data	NULL
were	NULL
analysed	NULL
neither	NULL
age	NULL
nor	NULL
menopausal	NULL
status	NULL
at	NULL
the	NULL
time	NULL
of	NULL
first	NULL
presentation	NULL
had	NULL
any	NULL
influence	NULL
on	NULL
the	NULL
recurrence	NULL
P=0.0004	NULL
28/30	NULL
U	NULL
~	NULL
#	NULL
.-	NULL
:	NULL
[	NULL
J	NULL
RP+ve	NULL
34/57	NULL
41/78	NULL
37/78	NULL
23/57	NULL
2/30	NULL
NONE	NULL
MODERATE	NULL
__	NULL
MARKED	NULL
LYMPHOCYTIC	NULL
INFILTRATION	NULL
Figure	NULL
4	NULL
-	NULL
Relationship	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
to	NULL
degree	NULL
of	NULL
lymphocytic	NULL
infiltration	NULL
of	NULL
primary	NULL
breast	NULL
cancers	NULL
.	NULL

634	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
IV	NULL
-	NULL
Summary	NULL
of	NULL
relationship	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
receptor	NULL
status	NULL
to	NULL
histological	NULL
observations	NULL
Association	NULL
with	NULL
oestrogen	NULL
receptor	NULL
(	NULL
RE	NULL
,	NULL
)	NULL
Association	NULL
with	NULL
Progesterone	NULL
receptor	NULL
(	NULL
RP	NULL
,	NULL
)	NULL
Histological	NULL
observation	NULL
Diameter	NULL
of	NULL
primary	NULL
tumour	NULL
None	NULL
Margin	NULL
of	NULL
primary	NULL
tumour	NULL
None	NULL
Histological	NULL
type	NULL
Grade	NULL
of	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
Lymphocytic	NULL
infiltration	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
P=0.0001	NULL
)	NULL
Epithelial	NULL
cellularity	NULL
:	NULL
Statistically	NULL
none	NULL
,	NULL
but	NULL
all	NULL
tubular	NULL
and	NULL
most	NULL
lobular	NULL
tumours	NULL
RE	NULL
,	NULL
+ve	NULL
RE	NULL
,	NULL
occur	NULL
most	NULL
frequently	NULL
in	NULL
grade	NULL
I	NULL
(	NULL
well-differentiated	NULL
)	NULL
tumours	NULL
(	NULL
P	NULL
=0.0004	NULL
)	NULL
Inverse	NULL
association	NULL
between	NULL
lymphoid	NULL
reaction	NULL
and	NULL
presence	NULL
In	NULL
RE	NULL
,	NULL
+ve	NULL
tumours	NULL
,	NULL
highest	NULL
values	NULL
None	NULL
None	NULL
Statistically	NULL
none	NULL
,	NULL
but	NULL
all	NULL
tubular	NULL
tumours	NULL
RP	NULL
,	NULL
+ve	NULL
RP	NULL
,	NULL
occur	NULL
most	NULL
frequently	NULL
in	NULL
grade	NULL
I	NULL
(	NULL
well-differentiated	NULL
)	NULL
tumours	NULL
(	NULL
P	NULL
=0.0001	NULL
)	NULL
Inverse	NULL
association	NULL
between	NULL
lymphoid	NULL
reaction	NULL
and	NULL
presence	NULL
of	NULL
RP	NULL
,	NULL
(	NULL
P=0.0004	NULL
)	NULL
none	NULL
in	NULL
most	NULL
cellular	NULL
tumours	NULL
(	NULL
postmenopausal	NULL
)	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
but	NULL
unrelated	NULL
to	NULL
receptor	NULL
status	NULL
Stromal	NULL
fibrosis	NULL
In	NULL
RE	NULL
,	NULL
+ve	NULL
tumours	NULL
,	NULL
lowest	NULL
values	NULL
None	NULL
in	NULL
those	NULL
tumours	NULL
with	NULL
marked	NULL
fibrosis	NULL
(	NULL
postmenopausal	NULL
)	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
but	NULL
unrelated	NULL
to	NULL
receptor	NULL
status	NULL
.	NULL

Elastosis	NULL
Number	NULL
of	NULL
axillary	NULL
nodes	NULL
containing	NULL
None	NULL
tumour	NULL
RE	NULL
,	NULL
occur	NULL
most	NULL
frequently	NULL
in	NULL
tumours	NULL
with	NULL
elastosis	NULL
(	NULL
P	NULL
=0.02	NULL
)	NULL
RP	NULL
,	NULL
occur	NULL
most	NULL
frequently	NULL
in	NULL
tumours	NULL
with	NULL
elastosis	NULL
(	NULL
P=0.004	NULL
)	NULL
None	NULL
rate	NULL
of	NULL
the	NULL
tumour	NULL
.	NULL

The	NULL
presence	NULL
or	NULL
absence	NULL
or	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
was	NULL
analysed	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
RFS	NULL
15	NULL
and	NULL
29	NULL
months	NULL
after	NULL
the	NULL
last	NULL
patient	NULL
entered	NULL
the	NULL
study	NULL
.	NULL

At	NULL
a	NULL
median	NULL
observation	NULL
period	NULL
of	NULL
24	NULL
months	NULL
,	NULL
a	NULL
statistically	NULL
significant	NULL
increase	NULL
in	NULL
RFS	NULL
was	NULL
found	NULL
for	NULL
patients	NULL
who	NULL
possessed	NULL
RE	NULL
,	NULL
compared	NULL
with	NULL
those	NULL
who	NULL
lacked	NULL
this	NULL
receptor	NULL
(	NULL
P	NULL
=0.02	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
was	NULL
no	NULL
longer	NULL
significant	NULL
at	NULL
a	NULL
median	NULL
period	NULL
of	NULL
observation	NULL
of	NULL
34	NULL
months	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
When	NULL
the	NULL
patients	NULL
were	NULL
divided	NULL
into	NULL
4	NULL
groups	NULL
according	NULL
to	NULL
the	NULL
RE	NULL
,	NULL
content	NULL
of	NULL
the	NULL
tumour	NULL
(	NULL
RE	NULL
,	NULL
negative	NULL
,	NULL
5-30	NULL
,	NULL
31-100	NULL
,	NULL
>	NULL
100fMmg~*	NULL
'	NULL
cytosol	NULL
protein	NULL
)	NULL
there	NULL
was	NULL
no	NULL
statistical	NULL
relationship	NULL
between	NULL
RFS	NULL
and	NULL
the	NULL
RE	NULL
,	NULL
,	NULL
value	NULL
at	NULL
any	NULL
time	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

In	NULL
163	NULL
patients	NULL
RP	NULL
,	NULL
was	NULL
also	NULL
measured	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
this	NULL
receptor	NULL
was	NULL
not	NULL
related	NULL
to	NULL
RFS	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

This	NULL
was	NULL
noted	NULL
in	NULL
both	NULL
RE	NULL
,	NULL
positive	NULL
and	NULL
RE	NULL
,	NULL
negative	NULL
tumours	NULL
,	NULL
although	NULL
the	NULL
number	NULL
of	NULL
patients	NULL
who	NULL
possessed	NULL
RP	NULL
,	NULL
and	NULL
lacked	NULL
RE	NULL
,	NULL
was	NULL
very	NULL
small	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
metastases	NULL
in	NULL
the	NULL
ipsilateral	NULL
axillary	NULL
nodes	NULL
in	NULL
determining	NULL
the	NULL
prognosis	NULL
in	NULL
breast	NULL
cancer	NULL
has	NULL
been	NULL
emphasised	NULL
(	NULL
Say	NULL
&	NULL
Donegan	NULL
,	NULL
1974	NULL
;	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

The	NULL
overall	NULL
recurrence	NULL
rate	NULL
was	NULL
significantly	NULL
higher	NULL
in	NULL
node	NULL
+ve	NULL
patients	NULL
regardless	NULL
of	NULL
their	NULL
receptor	NULL
status	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Three	NULL
years	NULL
after	NULL
mastectomy	NULL
80	NULL
%	NULL
of	NULL
patients	NULL
-	NULL
without	NULL
-	NULL
axillary	NULL
-	NULL
node	NULL
-	NULL
involvement	NULL
remained	NULL
free	NULL
from	NULL
recurrence	NULL
compared	NULL
with	NULL
56	NULL
%	NULL
of	NULL
those	NULL
who	NULL
had	NULL
1-3	NULL
involved	NULL
nodes	NULL
and	NULL
less	NULL
than	NULL
30	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
4	NULL
or	NULL
more	NULL
nodes	NULL
containing	NULL
tumour	NULL
.	NULL

RFS	NULL
was	NULL
analysed	NULL
in	NULL
relation	NULL
to	NULL
receptor	NULL
status	NULL
and	NULL
axillary	NULL
node	NULL
involvement	NULL
(	NULL
Figure	NULL
8	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
statistically	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
RFS	NULL
between	NULL
RE	NULL
,	NULL
+ve	NULL
and	NULL
RE	NULL
,	NULL
-ve	NULL
tumours	NULL
in	NULL
patients	NULL
without	NULL
axillary	NULL
metastases	NULL
(	NULL
P	NULL
>	NULL
0:9	NULL
)	NULL
or	NULL
in	NULL
patients	NULL
with	NULL
extensive	NULL
nodal	NULL
disease	NULL
(	NULL
24	NULL
)	NULL
(	NULL
P=0.2	NULL
)	NULL
.	NULL

In	NULL
patients	NULL
with	NULL
1-3	NULL
axillary	NULL
nodes	NULL
involved	NULL
,	NULL
RE	NULL
,	NULL
+ve	NULL
tumours	NULL
were	NULL
associated	NULL
with	NULL
a	NULL
longer	NULL
RFS	NULL
than	NULL
RE	NULL
,	NULL
-ve	NULL
tumours	NULL
at	NULL
a	NULL
median	NULL
observation	NULL
period	NULL
of	NULL
24	NULL
months	NULL
(	NULL
P=0.05	NULL
)	NULL
,	NULL
but	NULL
not	NULL
at	NULL
34	NULL
months	NULL
(	NULL
P=0.07	NULL
)	NULL
.	NULL

There	NULL
were	NULL
no	NULL
differences	NULL
between	NULL
the	NULL
RFS	NULL
of	NULL
RP	NULL
,	NULL
+ve	NULL
and	NULL
RP	NULL
,	NULL
-ve	NULL
tumours	NULL
in	NULL
any	NULL
axillary	NULL
node	NULL
subgroup	NULL
.	NULL

Discussion	NULL
Breast	NULL
cancer	NULL
varies	NULL
in	NULL
its	NULL
responsiveness	NULL
to	NULL
hormones	NULL
,	NULL
and	NULL
is	NULL
the	NULL
first	NULL
disease	NULL
in	NULL
which	NULL
estimation	NULL
of	NULL
tissue	NULL
receptors	NULL
at	NULL
the	NULL
time	NULL
of	NULL
initial	NULL
surgery	NULL
has	NULL
been	NULL
advocated	NULL
as	NULL
a	NULL
method	NULL
of	NULL
identifying	NULL
patients	NULL
with	NULL
the	NULL
greatest	NULL
risk	NULL
of	NULL
recurrence	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
examine	NULL
inter-relationships	NULL
between	NULL
steroid	NULL
receptor	NULL
activity	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
histological	NULL
features	NULL
,	NULL
and	NULL
to	NULL
HORMONE	NULL
RECEPTORS	NULL
IN	NULL
EARLY	NULL
BREAST	NULL
CANCER	NULL
635	NULL
RE	NULL
+ve	NULL
(	NULL
102	NULL
)	NULL
100	NULL
80	NULL
Ld	NULL
uJ	NULL
&	NULL
u|J	NULL
60	NULL
&	NULL
RE	NULL
,	NULL
(	NULL
73	NULL
)	NULL
e	NULL
a	NULL
)	NULL
ul	NULL
3	NULL
5	NULL
40-Lu	NULL
g	NULL
P=0.11	NULL
u	NULL
=V	NULL
S	NULL
20	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
1	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
MONTHS	NULL
Figure	NULL
5	NULL
-	NULL
Effect	NULL
of	NULL
RE	NULL
,	NULL
status	NULL
on	NULL
relapse-free	NULL
survival	NULL
.	NULL

assess	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
as	NULL
independent	NULL
factors	NULL
in	NULL
the	NULL
prognosis	NULL
of	NULL
breast	NULL
cancer	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
certain	NULL
factors	NULL
known	NULL
to	NULL
influence	NULL
the	NULL
natural	NULL
history	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
for	NULL
example	NULL
tumour	NULL
size	NULL
,	NULL
and	NULL
the	NULL
nature	NULL
of	NULL
its	NULL
margin	NULL
and	NULL
axillary	NULL
metastases	NULL
(	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
could	NULL
not	NULL
show	NULL
a	NULL
statistical	NULL
relationship	NULL
between	NULL
receptors	NULL
and	NULL
the	NULL
histological	NULL
type	NULL
it	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
all	NULL
tubular	NULL
carcinomas	NULL
had	NULL
both	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
.	NULL

This	NULL
confirms	NULL
the	NULL
observation	NULL
of	NULL
Antoniades	NULL
&	NULL
Spector	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

We	NULL
also	NULL
confirmed	NULL
reports	NULL
of	NULL
a	NULL
high	NULL
incidence	NULL
of	NULL
RE	NULL
,	NULL
in	NULL
invasive	NULL
lobular	NULL
tumours	NULL
(	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
;	NULL
Antoniades	NULL
&	NULL
Spector	NULL
,	NULL
1979	NULL
;	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979b	NULL
;	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Other	NULL
workers	NULL
have	NULL
failed	NULL
to	NULL
demonstrate	NULL
any	NULL
such	NULL
association	NULL
(	NULL
Johansson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1970	NULL
;	NULL
Feherty	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
Wittliff	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
LeClercq	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1973	NULL
;	NULL
Aspegren	NULL
&	NULL
Hakansson	NULL
,	NULL
1974	NULL
)	NULL
,	NULL
but	NULL
in	NULL
most	NULL
series	NULL
the	NULL
majority	NULL
of	NULL
tumours	NULL
were	NULL
infiltrating	NULL
duct	NULL
carcinomas	NULL
and	NULL
,	NULL
as	NULL
in	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
number	NULL
of	NULL
uncommon	NULL
histological	NULL
types	NULL
was	NULL
too	NULL
small	NULL
to	NULL
permit	NULL
statistical	NULL
evaluation	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
both	NULL
invasive	NULL
lobular	NULL
and	NULL
tubular	NULL
carcinomas	NULL
have	NULL
a	NULL
high	NULL
incidence	NULL
of	NULL
RE	NULL
,	NULL
,	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
they	NULL
are	NULL
extreme	NULL
variants	NULL
of	NULL
the	NULL
same	NULL
histological	NULL
entity	NULL
(	NULL
Eusebi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
)	NULL
.	NULL

Although	NULL
in	NULL
the	NULL
past	NULL
it	NULL
was	NULL
generally	NULL
accepted	NULL
that	NULL
there	NULL
was	NULL
no	NULL
association	NULL
between	NULL
the	NULL
presence	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
the	NULL
histological	NULL
features	NULL
of	NULL
infiltrating	NULL
duct	NULL
tumours	NULL
(	NULL
Johansson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1970	NULL
;	NULL
Feherty	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1971	NULL
;	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
,	NULL
only	NULL
Feherty	NULL
used	NULL
the	NULL
W.H.O	NULL
.	NULL

recommended	NULL
system	NULL
of	NULL
grading	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
using	NULL
this	NULL
method	NULL
exclusively	NULL
,	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
,	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1979b	NULL
)	NULL
,	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
and	NULL
Thoresen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
have	NULL
shown	NULL
a	NULL
definite	NULL
relationship	NULL
between	NULL
histological	NULL
grade	NULL
and	NULL
RE	NULL
,	NULL
.	NULL

Our	NULL
data	NULL
agree	NULL
with	NULL
the	NULL
latter	NULL
reports	NULL
and	NULL
in	NULL
addition	NULL
have	NULL
confirmed	NULL
the	NULL
findings	NULL
of	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1979b	NULL
)	NULL
that	NULL
the	NULL
possession	NULL
of	NULL
RP	NULL
,	NULL
is	NULL
also	NULL
linked	NULL
to	NULL
histological	NULL
grade	NULL
.	NULL

Terenius	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
was	NULL
unable	NULL
to	NULL
show	NULL
a	NULL
relationship	NULL
between	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
grade	NULL
,	NULL
but	NULL
found	NULL
that	NULL
RE	NULL
,	NULL
values	NULL
were	NULL
statistically	NULL
higher	NULL
in	NULL
well-differentiated	NULL
tumours	NULL
.	NULL

The	NULL
method	NULL
of	NULL
grading	NULL
was	NULL
not	NULL
specified	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
as	NULL
in	NULL
that	NULL
of	NULL
Heusen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
and	NULL
Thoresen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
,	NULL
the	NULL
mean	NULL
value	NULL
of	NULL
the	NULL
receptors	NULL
was	NULL
similar	NULL
in	NULL
all	NULL
three	NULL
grades	NULL
,	NULL
and	NULL
thus	NULL
the	NULL
significance	NULL
of	NULL
the	NULL
association	NULL
between	NULL
grade	NULL
and	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
receptor	NULL
is	NULL
difficult	NULL
to	NULL
interpret	NULL
.	NULL

Silvestrini	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
using	NULL
thymidine-labelling	NULL
indices	NULL
have	NULL
shown	NULL
that	NULL
tumours	NULL
with	NULL
rapid	NULL
rates	NULL
of	NULL
cell	NULL
division	NULL
have	NULL
a	NULL
low	NULL
636	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
er	NULL
al	NULL
.	NULL

100	NULL
80	NULL
2	NULL
(	NULL
42	NULL
)	NULL
iJ	NULL
60-7	NULL
l	NULL
&	NULL
3	NULL
(	NULL
24	NULL
)	NULL
u	NULL
(	NULL
36	NULL
)	NULL
F	NULL
73	NULL
fat	NULL
103	NULL
u	NULL
3	NULL
i-2	NULL
Ld	NULL
3	NULL
5	NULL
40-	NULL
P=0.3	NULL
a	NULL
.	NULL

1=RE	NULL
,	NULL
.-ve	NULL
2=5-30	NULL
fM	NULL
mg	NULL
~	NULL
'	NULL
3=31-100	NULL
fM	NULL
mg-	NULL
'	NULL
4=	NULL
>	NULL
100	NULL
fM	NULL
mg~	NULL
'	NULL
20	NULL
0	NULL
I	NULL
U	NULL
1	NULL
I	NULL
-	NULL
3	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
MONTHS	NULL
Figure	NULL
6	NULL
Effect	NULL
of	NULL
RE	NULL
,	NULL
value	NULL
on	NULL
relapse-free	NULL
survival	NULL
.	NULL

incidence	NULL
of	NULL
RE	NULL
,	NULL
.	NULL

This	NULL
,	NULL
and	NULL
the	NULL
frequency	NULL
with	NULL
which	NULL
receptors	NULL
are	NULL
found	NULL
in	NULL
low	NULL
grade	NULL
tumours	NULL
suggests	NULL
that	NULL
receptors	NULL
are	NULL
associated	NULL
in	NULL
some	NULL
way	NULL
with	NULL
low	NULL
rates	NULL
of	NULL
cellular	NULL
replication	NULL
.	NULL

Cellularity	NULL
,	NULL
when	NULL
assessed	NULL
both	NULL
at	NULL
the	NULL
centre	NULL
and	NULL
the	NULL
edge	NULL
of	NULL
the	NULL
tumour	NULL
to	NULL
avoid	NULL
sampling	NULL
errors	NULL
,	NULL
was	NULL
unrelated	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
.	NULL

However	NULL
,	NULL
in	NULL
receptor-positive	NULL
tumours	NULL
,	NULL
there	NULL
was	NULL
a	NULL
significant	NULL
association	NULL
between	NULL
the	NULL
highest	NULL
values	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
those	NULL
tumours	NULL
with	NULL
the	NULL
most	NULL
abundant	NULL
epithelial	NULL
component	NULL
.	NULL

This	NULL
was	NULL
found	NULL
both	NULL
in	NULL
the	NULL
overall	NULL
group	NULL
and	NULL
post-menopausal	NULL
patients	NULL
but	NULL
not	NULL
in	NULL
pre-menopausal	NULL
patients	NULL
Conversely	NULL
,	NULL
those	NULL
tumours	NULL
with	NULL
the	NULL
most	NULL
marked	NULL
stromal	NULL
reaction	NULL
had	NULL
the	NULL
lowest	NULL
RE	NULL
,	NULL
values	NULL
.	NULL

Once	NULL
again	NULL
this	NULL
was	NULL
not	NULL
seen	NULL
in	NULL
the	NULL
pre-menopausal	NULL
patients	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
HORMONE	NULL
RECEPTORS	NULL
IN	NULL
EARLY	NULL
BREAST	NULL
CANCER	NULL
637	NULL
100	NULL
80-w	NULL
LJ	NULL
&	NULL
C	NULL
``	NULL
t	NULL
eo-	NULL
RP_+ve	NULL
(	NULL
68	NULL
)	NULL
e	NULL
<	NULL
RP_-ve	NULL
(	NULL
95	NULL
)	NULL
-I	NULL
u	NULL
d	NULL
s	NULL
40	NULL
Ld	NULL
ed	NULL
cC	NULL
P=0.7	NULL
L	NULL
&	NULL
20	NULL
0	NULL
F	NULL
]	NULL
13	NULL
1	NULL
¥	NULL
U	NULL
1	NULL
*	NULL
``	NULL
montHs	NULL
°°	NULL
40	NULL
50	NULL
Figure	NULL
7	NULL
-	NULL
Effect	NULL
of	NULL
RP	NULL
,	NULL
status	NULL
on	NULL
relapse-free	NULL
survival	NULL
.	NULL

100	NULL
|__|—-|_	NULL
NO	NULL
,	NULL
RE.-ve	NULL
(	NULL
38	NULL
)	NULL
80	NULL
-1	NULL
a	NULL
N1-3	NULL
,	NULL
RE+ve	NULL
(	NULL
22	NULL
)	NULL
*	NULL
eo-	NULL
NO	NULL
,	NULL
RE+ve	NULL
(	NULL
61	NULL
)	NULL
uJ	NULL
'd	NULL
A	NULL
.	NULL

<	NULL
4	NULL
ad	NULL
L	NULL
C	NULL
&	NULL
C	NULL
z	NULL
40-ud	NULL
&	NULL
|	NULL
‘	NULL
&	NULL
no	NULL
RE	NULL
,	NULL
tve	NULL
v	NULL
RE.-ve	NULL
P	NULL
>	NULL
0.9	NULL
.-	NULL
N	NULL
34	NULL
,	NULL
RE	NULL
,	NULL
-ve	NULL
(	NULL
18	NULL
)	NULL
20	NULL
N1-3	NULL
_	NULL
RE	NULL
,	NULL
ve	NULL
v	NULL
RE-ve	NULL
P=0.07	NULL
Ni-3	NULL
,	NULL
Reve	NULL
(	NULL
17	NULL
)	NULL
~	NULL
N	NULL
*4	NULL
(	NULL
19	NULL
)	NULL
N	NULL
#	NULL
4	NULL
_	NULL
RE	NULL
+ve	NULL
v	NULL
RE	NULL
,	NULL
-ve	NULL
P=0.2	NULL
o	NULL
U	NULL
I	NULL
J	NULL
1	NULL
I	NULL
0	NULL
10	NULL
2	NULL
months	NULL
*	NULL
40	NULL
50	NULL
Figure	NULL
8	NULL
Effect	NULL
of	NULL
RE	NULL
,	NULL
status	NULL
and	NULL
node	NULL
involvement	NULL
on	NULL
relapse-free	NULL
survival	NULL
.	NULL

638	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
er	NULL
al	NULL
.	NULL

the	NULL
mean	NULL
value	NULL
of	NULL
the	NULL
progesterone	NULL
receptors	NULL
was	NULL
similar	NULL
for	NULL
all	NULL
degrees	NULL
of	NULL
cellularity	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
identical	NULL
with	NULL
those	NULL
of	NULL
Masters	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
and	NULL
similar	NULL
,	NULL
in	NULL
part	NULL
,	NULL
to	NULL
the	NULL
results	NULL
of	NULL
Terenius	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
,	NULL
Antoniades	NULL
&	NULL
Spector	NULL
(	NULL
1979	NULL
)	NULL
and	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1979a	NULL
)	NULL
.	NULL

Rosen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
observed	NULL
some	NULL
association	NULL
between	NULL
cellularity	NULL
and	NULL
RE	NULL
,	NULL
value	NULL
but	NULL
did	NULL
not	NULL
consider	NULL
it	NULL
significant	NULL
.	NULL

Feherty	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
and	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
were	NULL
unable	NULL
to	NULL
show	NULL
this	NULL
association	NULL
.	NULL

The	NULL
failure	NULL
to	NULL
demonstrate	NULL
such	NULL
a	NULL
link	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
unavoidable	NULL
variation	NULL
in	NULL
methods	NULL
used	NULL
to	NULL
assess	NULL
cellularity	NULL
(	NULL
Antoniades	NULL
&	NULL
Spector	NULL
,	NULL
1979	NULL
)	NULL
.	NULL

It	NULL
seems	NULL
that	NULL
although	NULL
cellularity	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
frequency	NULL
with	NULL
which	NULL
receptor-positive	NULL
tumours	NULL
are	NULL
identified	NULL
,	NULL
it	NULL
does	NULL
influence	NULL
the	NULL
value	NULL
of	NULL
RE	NULL
,	NULL
when	NULL
present	NULL
and	NULL
therefore	NULL
RE	NULL
,	NULL
negativity	NULL
,	NULL
based	NULL
on	NULL
a	NULL
low	NULL
receptor	NULL
value	NULL
,	NULL
should	NULL
be	NULL
considered	NULL
with	NULL
caution	NULL
in	NULL
tumours	NULL
of	NULL
low	NULL
cellularity	NULL
for	NULL
it	NULL
may	NULL
only	NULL
reflect	NULL
the	NULL
lack	NULL
of	NULL
epithelial	NULL
cells	NULL
(	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979a	NULL
)	NULL
.	NULL

As	NULL
the	NULL
presence	NULL
of	NULL
RP	NULL
,	NULL
is	NULL
normally	NULL
closely	NULL
linked	NULL
with	NULL
RE	NULL
,	NULL
(	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979b	NULL
)	NULL
the	NULL
dissociation	NULL
of	NULL
RE	NULL
,	NULL
and	NULL
RP	NULL
,	NULL
in	NULL
relation	NULL
to	NULL
cellularity	NULL
is	NULL
unexplained	NULL
.	NULL

There	NULL
is	NULL
no	NULL
readily	NULL
apparent	NULL
explanation	NULL
for	NULL
the	NULL
observation	NULL
that	NULL
receptors	NULL
occur	NULL
infrequently	NULL
in	NULL
tumours	NULL
with	NULL
a	NULL
prominent	NULL
lymphocytic	NULL
infiltration	NULL
,	NULL
a	NULL
relationship	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
previously	NULL
(	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
.	NULL

It	NULL
seems	NULL
unlikely	NULL
that	NULL
lymphocytes	NULL
per	NULL
se	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
absence	NULL
of	NULL
receptors	NULL
within	NULL
a	NULL
tumour	NULL
and	NULL
this	NULL
inverse	NULL
association	NULL
may	NULL
merely	NULL
reflect	NULL
the	NULL
observed	NULL
statistically	NULL
significant	NULL
association	NULL
between	NULL
heavy	NULL
lymphoid	NULL
-	NULL
infiltration	NULL
and	NULL
poorly	NULL
differentiated	NULL
tumours	NULL
.	NULL

A	NULL
lymphoid	NULL
reaction	NULL
is	NULL
known	NULL
to	NULL
be	NULL
closely	NULL
related	NULL
to	NULL
the	NULL
degree	NULL
of	NULL
malignancy	NULL
(	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1975	NULL
)	NULL
.	NULL

The	NULL
association	NULL
of	NULL
hormone	NULL
receptors	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
elastic	NULL
tissue	NULL
within	NULL
the	NULL
tumour	NULL
stroma	NULL
may	NULL
have	NULL
a	NULL
similar	NULL
explanation	NULL
for	NULL
there	NULL
was	NULL
a	NULL
statistical	NULL
association	NULL
between	NULL
histological	NULL
grade	NULL
and	NULL
elastosis	NULL
,	NULL
the	NULL
latter	NULL
being	NULL
most	NULL
marked	NULL
in	NULL
well-differentiated	NULL
(	NULL
grade	NULL
I	NULL
)	NULL
tumours	NULL
.	NULL

Masters	NULL
and	NULL
his	NULL
colleagues	NULL
(	NULL
1976	NULL
,	NULL
1978	NULL
)	NULL
and	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
have	NULL
also	NULL
found	NULL
an	NULL
association	NULL
between	NULL
RE	NULL
,	NULL
and	NULL
elastosis	NULL
,	NULL
a	NULL
feature	NULL
which	NULL
occurs	NULL
frequently	NULL
in	NULL
postmenopausal	NULL
patients	NULL
,	NULL
and	NULL
an	NULL
association	NULL
has	NULL
been	NULL
reported	NULL
between	NULL
RP	NULL
,	NULL
and	NULL
elastosis	NULL
(	NULL
Rolland	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
.	NULL

They	NULL
could	NULL
give	NULL
no-	NULL
satisfying	NULL
explanation	NULL
for	NULL
their	NULL
results	NULL
.	NULL

Shivas	NULL
&	NULL
Douglas	NULL
(	NULL
1972	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
patients	NULL
whose	NULL
tumours	NULL
contain	NULL
elastic	NULL
tissue	NULL
survive	NULL
longer	NULL
than	NULL
those	NULL
who	NULL
lack	NULL
it	NULL
.	NULL

They	NULL
are	NULL
also	NULL
more	NULL
likely	NULL
to	NULL
respond	NULL
to	NULL
endocrine	NULL
therapy	NULL
(	NULL
Masters	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
)	NULL
.	NULL

Well-differentiated	NULL
(	NULL
grade	NULL
I	NULL
)	NULL
tumours	NULL
have	NULL
similar	NULL
properties	NULL
(	NULL
McGuire	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
.	NULL

These	NULL
reports	NULL
taken	NULL
with	NULL
the	NULL
present	NULL
data	NULL
emphasise	NULL
that	NULL
hormone-dependent	NULL
cells	NULL
in	NULL
breast	NULL
tumours	NULL
can	NULL
be	NULL
demonstrated	NULL
both	NULL
biochemically	NULL
and	NULL
histologically	NULL
and	NULL
many	NULL
of	NULL
the	NULL
features	NULL
of	NULL
breast	NULL
cancer	NULL
are	NULL
interdependent	NULL
.	NULL

Steroid	NULL
receptors	NULL
can	NULL
not	NULL
be	NULL
considered	NULL
in	NULL
isolation	NULL
when	NULL
planning	NULL
treatment	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
receptor	NULL
status	NULL
and	NULL
prognosis	NULL
is	NULL
not	NULL
a	NULL
simple	NULL
one	NULL
.	NULL

Several	NULL
reports	NULL
have	NULL
suggested	NULL
that	NULL
early	NULL
relapse	NULL
of	NULL
breast	NULL
cancer	NULL
is	NULL
clearly	NULL
associated	NULL
with	NULL
a	NULL
lack	NULL
of	NULL
RE	NULL
,	NULL
(	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Cooke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
,	NULL
1980	NULL
;	NULL
Allegra	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Hahnel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Forrest	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Westerberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
.	NULL

Patients	NULL
who	NULL
have	NULL
RE	NULL
,	NULL
are	NULL
reported	NULL
to	NULL
live	NULL
longer	NULL
than	NULL
those	NULL
who	NULL
lack	NULL
it	NULL
(	NULL
Bishop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Croton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Kinne	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
and	NULL
Samaan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
found	NULL
no	NULL
overall	NULL
difference	NULL
in	NULL
the	NULL
RFS	NULL
of	NULL
patients	NULL
with	NULL
and	NULL
without	NULL
RE	NULL
,	NULL
but	NULL
have	NULL
found	NULL
small	NULL
significant	NULL
differences	NULL
in	NULL
subgroups	NULL
based	NULL
on	NULL
node	NULL
or	NULL
menopausal	NULL
status	NULL
.	NULL

The	NULL
data	NULL
from	NULL
the	NULL
present	NULL
study	NULL
,	NULL
like	NULL
those	NULL
of	NULL
Hilf	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
fails	NULL
to	NULL
demonstrate	NULL
any	NULL
clear	NULL
prognostic	NULL
value	NULL
for	NULL
disease	NULL
recurrence	NULL
.	NULL

Similarly	NULL
there	NULL
is	NULL
conflicting	NULL
evidence	NULL
that	NULL
the	NULL
progesterone	NULL
receptor	NULL
is	NULL
a	NULL
reliable	NULL
indicator	NULL
of	NULL
prognosis	NULL
.	NULL

Pichon	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
demonstrated	NULL
an	NULL
increase	NULL
in	NULL
RFS	NULL
for	NULL
patients	NULL
with	NULL
RP	NULL
,	NULL
whereas	NULL
Allegra	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
and	NULL
Kinne	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
as	NULL
in	NULL
the	NULL
present	NULL
study	NULL
,	NULL
found	NULL
no	NULL
association	NULL
between	NULL
the	NULL
RP	NULL
,	NULL
,	NULL
and	NULL
RFS	NULL
.	NULL

The	NULL
reasons	NULL
for	NULL
these	NULL
conflicting	NULL
results	NULL
are	NULL
not	NULL
clear	NULL
.	NULL

Variations	NULL
in	NULL
the	NULL
method	NULL
of	NULL
receptor	NULL
analysis	NULL
may	NULL
be	NULL
important	NULL
and	NULL
Forrest	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
showed	NULL
that	NULL
by	NULL
merely	NULL
moving	NULL
the	NULL
``	NULL
cut-off	NULL
point	NULL
``	NULL
separating	NULL
receptor-rich	NULL
(	NULL
+ve	NULL
)	NULL
from	NULL
receptor-poor	NULL
(	NULL
low	NULL
+ve	NULL
and	NULL
-ve	NULL
)	NULL
tumours	NULL
,	NULL
the	NULL
prognostic	NULL
value	NULL
for	NULL
RE	NULL
,	NULL
could	NULL
be	NULL
eliminated	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
good	NULL
qualitative	NULL
agreement	NULL
between	NULL
centres	NULL
using	NULL
the	NULL
DCC	NULL
technique	NULL
,	NULL
including	NULL
our	NULL
own	NULL
(	NULL
King	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
)	NULL
,	NULL
and	NULL
the	NULL
present	NULL
study	NULL
has	NULL
employed	NULL
similar	NULL
criteria	NULL
for	NULL
receptor	NULL
positivity	NULL
to	NULL
previous	NULL
reports	NULL
.	NULL

Hilf	NULL
and	NULL
his	NULL
colleagues	NULL
(	NULL
1980	NULL
)	NULL
stressed	NULL
that	NULL
clinical	NULL
factors	NULL
may	NULL
cause	NULL
confusion	NULL
in	NULL
interpreting	NULL
data	NULL
relating	NULL
RE	NULL
,	NULL
status	NULL
to	NULL
prognosis	NULL
,	NULL
and	NULL
their	NULL
observations	NULL
may	NULL
also	NULL
apply	NULL
to	NULL
RP	NULL
,	NULL
.	NULL

In	NULL
early	NULL
studies	NULL
numbers	NULL
were	NULL
small	NULL
or	NULL
receptor	NULL
data	NULL
from	NULL
primary	NULL
and	NULL
secondary	NULL
tumours	NULL
were	NULL
combined	NULL
.	NULL

In	NULL
some	NULL
,	NULL
no	NULL
allowance	NULL
was	NULL
made	NULL
for	NULL
patients	NULL
receiving	NULL
additional	NULL
systemic	NULL
or	NULL
local	NULL
treatment	NULL
following	NULL
mastectomy	NULL
,	NULL
in	NULL
others	NULL
,	NULL
the	NULL
status	NULL
of	NULL
the	NULL
axillary	NULL
nodes	NULL
was	NULL
not	NULL
accurately	NULL
known	NULL
,	NULL
staging	NULL
being	NULL
based	NULL
on	NULL
pectoral	NULL
node	NULL
biopsy	NULL
,	NULL
a	NULL
technique	NULL
which	NULL
in	NULL
our	NULL
experience	NULL
may	NULL
give	NULL
a	NULL
false-negative	NULL
rate	NULL
of	NULL
axillary	NULL
node	NULL
involvement	NULL
as	NULL
high	NULL
as	NULL
20	NULL
%	NULL
,	NULL
(	NULL
Howat	NULL
&	NULL
Harris	NULL
,	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
length	NULL
of	NULL
follow-up	NULL
is	NULL
short	NULL
in	NULL
many	NULL
of	NULL
the	NULL
reports	NULL
claiming	NULL
prolonged	NULL
RFS	NULL
(	NULL
Knight	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
;	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1978	NULL
;	NULL
Pichon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
)	NULL
,	NULL
and	NULL
actual	NULL
survival	NULL
(	NULL
Bishop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
;	NULL
Croton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
for	NULL
receptor	NULL
+ve	NULL
patients	NULL
.	NULL

Our	NULL
experience	NULL
has	NULL
emphasised	NULL
the	NULL
importance	NULL
of	NULL
prolonged	NULL
follow	NULL
HORMONE	NULL
RECEPTORS	NULL
IN	NULL
EARLY	NULL
BREAST	NULL
CANCER	NULL
639	NULL
up	NULL
.	NULL

At	NULL
a	NULL
median	NULL
follow-up	NULL
of	NULL
24	NULL
months	NULL
our	NULL
results	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
Knight	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
,	NULL
Maynard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
and	NULL
Kinne	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
an	NULL
increase	NULL
in	NULL
RFS	NULL
for	NULL
RE	NULL
,	NULL
+ve	NULL
patients	NULL
with	NULL
lymph	NULL
node	NULL
involvement	NULL
,	NULL
but	NULL
not	NULL
for	NULL
any	NULL
other	NULL
sub-group	NULL
.	NULL

The	NULL
data	NULL
suggested	NULL
that	NULL
only	NULL
those	NULL
with	NULL
minimal	NULL
axillary	NULL
disease	NULL
(	NULL
1-3	NULL
nodes	NULL
)	NULL
benefitted	NULL
and	NULL
it	NULL
was	NULL
thought	NULL
that	NULL
too	NULL
few	NULL
node	NULL
-ve	NULL
patients	NULL
had	NULL
recurred	NULL
to	NULL
show	NULL
any	NULL
difference	NULL
attributable	NULL
to	NULL
the	NULL
RE	NULL
,	NULL
status	NULL
and	NULL
that	NULL
patients	NULL
with	NULL
extensive	NULL
nodal	NULL
involvement	NULL
(	NULL
24	NULL
)	NULL
had	NULL
recurred	NULL
too	NULL
rapidly	NULL
for	NULL
any	NULL
beneficial	NULL
effect	NULL
of	NULL
RE	NULL
,	NULL
to	NULL
become	NULL
apparent	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
median	NULL
follow-up	NULL
reached	NULL
34	NULL
months	NULL
the	NULL
difference	NULL
between	NULL
RE	NULL
,	NULL
+ve	NULL
and	NULL
RE	NULL
,	NULL
-ve	NULL
patients	NULL
in	NULL
the	NULL
1-3	NULL
node	NULL
subgroup	NULL
had	NULL
disappeared	NULL
.	NULL

Hahnel	NULL
and	NULL
his	NULL
colleagues	NULL
(	NULL
1979	NULL
)	NULL
made	NULL
similar	NULL
observations	NULL
.	NULL

An	NULL
apparently	NULL
advantageous	NULL
effect	NULL
of	NULL
the	NULL
RE	NULL
,	NULL
in	NULL
node	NULL
+ve	NULL
patients	NULL
seen	NULL
in	NULL
the	NULL
first	NULL
2	NULL
years	NULL
after	NULL
mastectomy	NULL
disappeared	NULL
so	NULL
that	NULL
at	NULL
5	NULL
years	NULL
they	NULL
too	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
a	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
RFS	NULL
of	NULL
RE	NULL
,	NULL
+ve	NULL
and	NULL
-ve	NULL
patients	NULL
in	NULL
any	NULL
subgroup	NULL
.	NULL

Von	NULL
Maillot	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
obtained	NULL
similar	NULL
results	NULL
for	NULL
both	NULL
RE	NULL
,	NULL
+ve	NULL
and	NULL
RP	NULL
,	NULL
+ve	NULL
patients	NULL
when	NULL
they	NULL
were	NULL
compared	NULL
with	NULL
receptor-negative	NULL
cases	NULL
.	NULL

Benson	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
made	NULL
similar	NULL
observations	NULL
on	NULL
survival	NULL
.	NULL

At	NULL
5	NULL
years	NULL
References	NULL
ALLEGRA	NULL
,	NULL
J.C.	NULL
,	NULL
LIPPMAN	NULL
,	NULL
ME	NULL
.	NULL

,	NULL
SIMON	NULL
,	NULL
R.	NULL
&	NULL
7	NULL
others	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
.	NULL

Association	NULL
between	NULL
steroid	NULL
hormone	NULL
receptor	NULL
status	NULL
and	NULL
disease	NULL
free	NULL
interval	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
Treat	NULL
.	NULL

Rep.	NULL
,	NULL
63	NULL
,	NULL
1271	NULL
.	NULL

ANTONIADES	NULL
,	NULL
K.	NULL
&	NULL
SPECTOR	NULL
,	NULL
H.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Correlation	NULL
of	NULL
oestrogen	NULL
-	NULL
receptor	NULL
levels	NULL
with	NULL
histology	NULL
-	NULL
and	NULL
cytomorphology	NULL
in	NULL
human	NULL
mammary	NULL
cancer	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
71	NULL
,	NULL
497	NULL
.	NULL

ASPEGREN	NULL
,	NULL
K.	NULL
&	NULL
HAKANSSON	NULL
,	NULL
L.	NULL
(	NULL
1974	NULL
)	NULL
.	NULL

Human	NULL
mammary	NULL
_	NULL
carcinoma	NULL
_	NULL
studied	NULL
_-	NULL
for	NULL
-	NULL
hormone	NULL
responsiveness	NULL
in	NULL
short	NULL
term	NULL
incubations	NULL
.	NULL

Acta	NULL
.	NULL

Chir	NULL
.	NULL

Scand	NULL
.	NULL

,	NULL
140	NULL
,	NULL
95	NULL
.	NULL

BARNES	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
RIBEIRO	NULL
,	NULL
G.G	NULL
.	NULL

&	NULL
SKINNER	NULL
,	NULL
LG	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

Two	NULL
methods	NULL
for	NULL
measurement	NULL
of	NULL
oestradiol-178	NULL
and	NULL
progesterone	NULL
receptors	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
and	NULL
correlation	NULL
with	NULL
response	NULL
to	NULL
treatment	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
13	NULL
,	NULL
1133	NULL
.	NULL

BENSON	NULL
,	NULL
EA	NULL
.	NULL

,	NULL
CARTWRIGHT	NULL
,	NULL
R.A.	NULL
,	NULL
COWEN	NULL
,	NULL
PN	NULL
.	NULL

&	NULL
HAMILTON	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptors	NULL
and	NULL
survival	NULL
in	NULL
early	NULL
breast	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J.	NULL
,	NULL
284	NULL
,	NULL
597	NULL
.	NULL

BISHOP	NULL
,	NULL
H.M.	NULL
,	NULL
BLAMEY	NULL
,	NULL
RW	NULL
.	NULL

,	NULL
ELSTON	NULL
,	NULL
C.W	NULL
.	NULL

,	NULL
HAYBRITTLE	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
NICHOLSON	NULL
,	NULL
R.I.	NULL
&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Relationship	NULL
of	NULL
cestrogen-receptor	NULL
status	NULL
to	NULL
survival	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Lancet	NULL
,	NULL
ii	NULL
,	NULL
283	NULL
.	NULL

BLOOM	NULL
,	NULL
H.J.G	NULL
.	NULL

&	NULL
RICHARDSON	NULL
,	NULL
W.W.	NULL
(	NULL
1957	NULL
)	NULL
.	NULL

Histological	NULL
grading	NULL
and	NULL
prognosis	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
11	NULL
,	NULL
359	NULL
.	NULL

COOKE	NULL
,	NULL
T.	NULL
,	NULL
GEORGE	NULL
,	NULL
W.D	NULL
.	NULL

&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Possible	NULL
tests	NULL
for	NULL
selection	NULL
of	NULL
adjuvant	NULL
systemic	NULL
therapy	NULL
in	NULL
early	NULL
cancer	NULL
of	NULL
the	NULL
breast	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Surg	NULL
.	NULL

,	NULL
67	NULL
,	NULL
747.	NULL
there	NULL
was	NULL
no	NULL
benefit	NULL
for	NULL
RE	NULL
,	NULL
+ve	NULL
patients	NULL
despite	NULL
an	NULL
earlier	NULL
trend	NULL
in	NULL
their	NULL
favour	NULL
.	NULL

It	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
the	NULL
progesterone	NULL
receptor	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
RFS	NULL
in	NULL
this	NULL
study	NULL
for	NULL
its	NULL
presence	NULL
is	NULL
closely	NULL
linked	NULL
to	NULL
that	NULL
of	NULL
RE	NULL
,	NULL
.	NULL

Thus	NULL
one	NULL
might	NULL
expect	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
effect	NULL
on	NULL
RFS	NULL
of	NULL
the	NULL
RE	NULL
,	NULL
would	NULL
be	NULL
reflected	NULL
in	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
RP	NULL
;	NULL
.	NULL

_	NULL
As	NULL
the	NULL
data	NULL
obtained	NULL
in	NULL
our	NULL
study	NULL
did	NULL
not	NULL
demonstrate	NULL
any	NULL
marked	NULL
prognostic	NULL
value	NULL
for	NULL
either	NULL
RE	NULL
,	NULL
or	NULL
RP	NULL
,	NULL
status	NULL
and	NULL
as	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
receptors	NULL
may	NULL
merely	NULL
reflect	NULL
more	NULL
easily	NULL
assessed	NULL
histological	NULL
features	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
measurement	NULL
of	NULL
these	NULL
receptors	NULL
is	NULL
of	NULL
no	NULL
value	NULL
in	NULL
identifying	NULL
those	NULL
patients	NULL
at	NULL
greatest	NULL
risk	NULL
of	NULL
recurrence	NULL
.	NULL

Other	NULL
factors	NULL
such	NULL
as	NULL
tumour	NULL
size	NULL
and	NULL
axillary	NULL
node	NULL
status	NULL
remain	NULL
pre-eminent	NULL
as	NULL
reliable	NULL
guides	NULL
to	NULL
prognosis	NULL
.	NULL

The	NULL
authors	NULL
are	NULL
grateful	NULL
to	NULL
Prof	NULL
,	NULL
R.A.	NULL
Sellwood	NULL
for	NULL
permission	NULL
to	NULL
study	NULL
patients	NULL
in	NULL
his	NULL
care	NULL
and	NULL
Dr.	NULL
H.	NULL
Bush	NULL
,	NULL
Dr.	NULL
A.	NULL
Howell	NULL
,	NULL
Mr.	NULL
R.N.L	NULL
.	NULL

Harland	NULL
,	NULL
Mr.	NULL
M.J.	NULL
Hudson	NULL
and	NULL
Mr.	NULL
L.G	NULL
.	NULL

Skinner	NULL
,	NULL
for	NULL
their	NULL
interest	NULL
and	NULL
invaluable	NULL
advice	NULL
given	NULL
during	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
paper	NULL
.	NULL

Ms	NULL
E.	NULL
Hayward	NULL
gave	NULL
expert	NULL
technical	NULL
assistance	NULL
and	NULL
Ms	NULL
L.	NULL
Shaughnessy	NULL
typed	NULL
the	NULL
manuscript	NULL
.	NULL

COOKE	NULL
,	NULL
T.	NULL
,	NULL
GEORGE	NULL
,	NULL
D.	NULL
,	NULL
SHIELDS	NULL
,	NULL
R.	NULL
,	NULL
MAYNARD	NULL
,	NULL
P.	NULL
&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptors	NULL
and	NULL
prognosis	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Lancer	NULL
,	NULL
i	NULL
,	NULL
995	NULL
.	NULL

CROTON	NULL
,	NULL
R.	NULL
,	NULL
COOKE	NULL
,	NULL
T.	NULL
,	NULL
HOLT	NULL
,	NULL
S.	NULL
,	NULL
GEORGE	NULL
,	NULL
W.D	NULL
.	NULL

,	NULL
NICHOLSON	NULL
,	NULL
R.	NULL
&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptors	NULL
and	NULL
survival	NULL
in	NULL
early	NULL
breast	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J.	NULL
,	NULL
283	NULL
,	NULL
1289	NULL
.	NULL

EUSEBI	NULL
,	NULL
V.	NULL
,	NULL
BETTS	NULL
,	NULL
C.M	NULL
.	NULL

&	NULL
BUSSOLATI	NULL
,	NULL
G.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Tubular	NULL
carcinoma	NULL
:	NULL
a	NULL
variant	NULL
of	NULL
secretory	NULL
breast	NULL
carcinoma	NULL
.	NULL

Histopathology	NULL
,	NULL
3	NULL
,	NULL
407	NULL
.	NULL

FEHERTY	NULL
,	NULL
P.	NULL
,	NULL
FARRER-BROWN	NULL
,	NULL
G.	NULL
&	NULL
KELLIE	NULL
,	NULL
AE	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
.	NULL

Oestradiol	NULL
receptors	NULL
in	NULL
carcinoma	NULL
and	NULL
benign	NULL
disease	NULL
of	NULL
the	NULL
breast	NULL
:	NULL
An	NULL
in	NULL
vitro	NULL
assay	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
25	NULL
,	NULL
697	NULL
.	NULL

FISHER	NULL
,	NULL
E.R	NULL
.	NULL

,	NULL
GREGORIO	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
FISHER	NULL
,	NULL
B.	NULL
,	NULL
REDMOND	NULL
,	NULL
C.	NULL
,	NULL
VELLIOS	NULL
,	NULL
F.	NULL
&	NULL
SOMMERS	NULL
,	NULL
S.C.	NULL
(	NULL
1975	NULL
)	NULL
.	NULL

The	NULL
pathology	NULL
of	NULL
invasive	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
36	NULL
,	NULL
1	NULL
.	NULL

FORREST	NULL
,	NULL
A.P.M	NULL
.	NULL

,	NULL
BLACK	NULL
,	NULL
RB	NULL
.	NULL

,	NULL
HUMENIUK	NULL
,	NULL
V.	NULL
&	NULL
8	NULL
others	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Preoperative	NULL
assessment	NULL
and	NULL
staging	NULL
of	NULL
breast	NULL
cancer	NULL
:	NULL
preliminary	NULL
communication	NULL
.	NULL

J.	NULL
R.	NULL
Soc	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
73	NULL
,	NULL
561	NULL
.	NULL

HAHNEL	NULL
,	NULL
R.	NULL
,	NULL
WOODINGS	NULL
,	NULL
T.	NULL
&	NULL
VIVIAN	NULL
,	NULL
A.B	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
.	NULL

Prognostic	NULL
value	NULL
of	NULL
oestrogen	NULL
receptors	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
44	NULL
,	NULL
671	NULL
.	NULL

HEUSEN	NULL
,	NULL
J.C.	NULL
,	NULL
LECLERCQ	NULL
,	NULL
G.	NULL
,	NULL
LONGEVAL	NULL
,	NULL
E.	NULL
,	NULL
DEBOEL	NULL
,	NULL
M.C	NULL
.	NULL

,	NULL
MATTHEIEM	NULL
,	NULL
W.H	NULL
.	NULL

&	NULL
HEIMANN	NULL
,	NULL
R.	NULL
(	NULL
1975	NULL
)	NULL
.	NULL

Estrogen	NULL
receptors	NULL
:	NULL
Prognostic	NULL
significance	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

In	NULL
Estrogen	NULL
Receptors	NULL
in	NULL
Human	NULL
Breast	NULL
Cancer	NULL
,	NULL
(	NULL
Eds	NULL
.	NULL

McGuire	NULL
et	NULL
a/	NULL
.	NULL
)	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
.	NULL

p.	NULL
57	NULL
.	NULL

HILF	NULL
,	NULL
R.	NULL
,	NULL
FELDSTEIN	NULL
,	NULL
ML	NULL
.	NULL

,	NULL
SCOTT	NULL
,	NULL
G.L	NULL
.	NULL

&	NULL
SAVLOY	NULL
,	NULL
ED	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
importance	NULL
of	NULL
estrogen	NULL
receptor	NULL
640	NULL
J.M.T	NULL
.	NULL

HOWAT	NULL
et	NULL
al	NULL
.	NULL

analysis	NULL
as	NULL
a	NULL
prognostic	NULL
factor	NULL
for	NULL
recurrence	NULL
or	NULL
response	NULL
to	NULL
chemotherapy	NULL
in	NULL
women	NULL
with	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
45	NULL
,	NULL
1993	NULL
.	NULL

HOWAT	NULL
,	NULL
J.M.T	NULL
.	NULL

&	NULL
HARRIS	NULL
,	NULL
M.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Axillary	NULL
sampling	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Lancet	NULL
,	NULL
ii	NULL
,	NULL
37	NULL
.	NULL

JOHANSSON	NULL
,	NULL
H.	NULL
,	NULL
TERENIUS	NULL
,	NULL
L.	NULL
&	NULL
THOREN	NULL
,	NULL
L.	NULL
(	NULL
1970	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
estradiol-178	NULL
to	NULL
human	NULL
breast	NULL
cancer	NULL
and	NULL
other	NULL
tissues	NULL
in	NULL
vitro	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
30	NULL
,	NULL
692	NULL
.	NULL

KING	NULL
,	NULL
R.J.B	NULL
.	NULL

,	NULL
BARNES	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
HAWKINS	NULL
,	NULL
R.A.	NULL
,	NULL
LEAKE	NULL
,	NULL
RE	NULL
.	NULL

,	NULL
MAYNARD	NULL
,	NULL
PV	NULL
.	NULL

&	NULL
ROBERTS	NULL
,	NULL
MM	NULL
.	NULL

(	NULL
1978	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
oestradiol	NULL
receptors	NULL
by	NULL
-	NULL
five	NULL
institutions	NULL
on	NULL
common	NULL
tissue	NULL
samples	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
38	NULL
,	NULL
428	NULL
.	NULL

KINNE	NULL
,	NULL
D.W.	NULL
,	NULL
ASHIKARI	NULL
,	NULL
R.	NULL
,	NULL
BUTLER	NULL
,	NULL
A.	NULL
,	NULL
MENENDEZ-BOTET	NULL
,	NULL
C.	NULL
,	NULL
ROSEN	NULL
,	NULL
P.P	NULL
.	NULL

&	NULL
SCHWARTZ	NULL
,	NULL
M.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Estrogen	NULL
receptor	NULL
protein	NULL
in	NULL
breast	NULL
cancer	NULL
as	NULL
a	NULL
predictor	NULL
of	NULL
recurrence	NULL
.	NULL

Cancer	NULL
,	NULL
47	NULL
,	NULL
2364	NULL
.	NULL

KNIGHT	NULL
,	NULL
W.A	NULL
.	NULL

,	NULL
LIVINGSTON	NULL
,	NULL
RB	NULL
.	NULL

,	NULL
GREGORY	NULL
,	NULL
EJ	NULL
.	NULL

&	NULL
MCGUIRE	NULL
,	NULL
WL	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

Estrogen	NULL
receptor	NULL
as	NULL
an	NULL
independent	NULL
prognostic	NULL
factor	NULL
for	NULL
early	NULL
recurrence	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
,	NULL
4669	NULL
.	NULL

KORENMAN	NULL
,	NULL
S.G.	NULL
&	NULL
DUKES	NULL
,	NULL
BA	NULL
.	NULL

(	NULL
1970	NULL
)	NULL
.	NULL

Specific	NULL
oestrogen	NULL
binding	NULL
by	NULL
the	NULL
cytoplasm	NULL
of	NULL
human	NULL
breast	NULL
carcinoma	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
30	NULL
,	NULL
639	NULL
.	NULL

LECLERCQ	NULL
,	NULL
G.	NULL
,	NULL
HEUSON	NULL
,	NULL
J.C.	NULL
,	NULL
SCHOENFIELD	NULL
,	NULL
R.	NULL
,	NULL
MATTHEIEM	NULL
,	NULL
W.J	NULL
.	NULL

&	NULL
TAGNON	NULL
,	NULL
H.J	NULL
.	NULL

(	NULL
1973	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptors	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
9	NULL
,	NULL
665	NULL
.	NULL

MARTIN	NULL
,	NULL
P.M.	NULL
,	NULL
ROLLAND	NULL
,	NULL
PH	NULL
.	NULL

,	NULL
JACQUEMIER	NULL
,	NULL
J.	NULL
,	NULL
ROLLAND	NULL
,	NULL
A.M.	NULL
&	NULL
TOGA	NULL
,	NULL
M.	NULL
(	NULL
19794	NULL
)	NULL
.	NULL

Multiple	NULL
steroid	NULL
receptors	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

II	NULL
Oestrogen	NULL
and	NULL
progestin	NULL
receptors	NULL
in	NULL
672	NULL
primary	NULL
tumours	NULL
.	NULL

Cancer	NULL
Chemother	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
107	NULL
.	NULL

MARTIN	NULL
,	NULL
P.M.	NULL
,	NULL
ROLLAND	NULL
,	NULL
PH	NULL
.	NULL

,	NULL
JACQUEMIER	NULL
,	NULL
J.	NULL
,	NULL
ROLLAND	NULL
,	NULL
A.M.	NULL
&	NULL
TOGA	NULL
,	NULL
M.	NULL
(	NULL
19796	NULL
)	NULL
.	NULL

Multiple	NULL
steroid	NULL
receptors	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

III	NULL
Relationships	NULL
between	NULL
-	NULL
steroid	NULL
receptors	NULL
and	NULL
the	NULL
state	NULL
-	NULL
of	NULL
differentiation	NULL
-	NULL
and	NULL
the	NULL
-	NULL
activity	NULL
of	NULL
-	NULL
carcinomas	NULL
throughout	NULL
-	NULL
the	NULL
-	NULL
pathological	NULL
-	NULL
features	NULL
.	NULL

-	NULL
Cancer	NULL
Chemother	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
115	NULL
.	NULL

MASTERS	NULL
,	NULL
J.R.W	NULL
.	NULL

,	NULL
HAWKINS	NULL
,	NULL
R.A.	NULL
,	NULL
SANGSTER	NULL
,	NULL
K.	NULL
&	NULL
5	NULL
others	NULL
(	NULL
1978	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptors	NULL
,	NULL
cellularity	NULL
,	NULL
elastosis	NULL
and	NULL
menstrual	NULL
status	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
14	NULL
,	NULL
303	NULL
.	NULL

MASTERS	NULL
,	NULL
J.R.W	NULL
.	NULL

,	NULL
MILLIS	NULL
,	NULL
RR	NULL
.	NULL

,	NULL
KING	NULL
,	NULL
R.J.B	NULL
.	NULL

&	NULL
RUBENS	NULL
,	NULL
RD	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
.	NULL

Elastosis	NULL
and	NULL
response	NULL
to	NULL
endocrine	NULL
therapy	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
39	NULL
,	NULL
536	NULL
.	NULL

MASTERS	NULL
,	NULL
J.R.W	NULL
.	NULL

,	NULL
SANGSTER	NULL
,	NULL
K.	NULL
,	NULL
HAWKINS	NULL
,	NULL
RA	NULL
.	NULL

&	NULL
SHIVAS	NULL
,	NULL
A.A.	NULL
(	NULL
1976	NULL
)	NULL
.	NULL

Elastosis	NULL
and	NULL
oestrogen	NULL
receptors	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
33	NULL
,	NULL
342	NULL
.	NULL

MAYNARD	NULL
,	NULL
PV	NULL
.	NULL

,	NULL
BLAMEY	NULL
,	NULL
RW	NULL
.	NULL

,	NULL
ELSTON	NULL
,	NULL
CW	NULL
.	NULL

,	NULL
HAYBRITTLE	NULL
,	NULL
J.L	NULL
.	NULL

&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1978	NULL
)	NULL
.	NULL

Estrogen	NULL
receptor	NULL
assay	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
and	NULL
early	NULL
recurrence	NULL
of	NULL
disease	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
,	NULL
4292	NULL
.	NULL

MAYNARD	NULL
,	NULL
P.V	NULL
.	NULL

,	NULL
DAVIES	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
BLAMEY	NULL
,	NULL
R.W	NULL
.	NULL

,	NULL
ELSTON	NULL
,	NULL
C.W	NULL
.	NULL

,	NULL
JOHNSTON	NULL
,	NULL
J	NULL
.	NULL

&	NULL
GRIFFITHS	NULL
,	NULL
K.	NULL
(	NULL
1978	NULL
)	NULL
.	NULL

Relationship	NULL
between	NULL
oestrogen	NULL
receptor	NULL
content	NULL
and	NULL
histological	NULL
grade	NULL
in	NULL
human	NULL
primary	NULL
breast	NULL
tumour	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
38	NULL
,	NULL
745.	NULL
.	NULL

MCGUIRE	NULL
,	NULL
WL	NULL
.	NULL

,	NULL
HORWITZ	NULL
,	NULL
K.B	NULL
.	NULL

,	NULL
PEARSON	NULL
,	NULL
O.H	NULL
.	NULL

&	NULL
SEGALOFF	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

Current	NULL
status	NULL
of	NULL
oestrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
39	NULL
,	NULL
2934	NULL
.	NULL

MILLIS	NULL
,	NULL
RR	NULL
.	NULL

,	NULL
RUBENS	NULL
,	NULL
RD	NULL
.	NULL

,	NULL
MASTERS	NULL
,	NULL
JRW	NULL
.	NULL

&	NULL
MINTON	NULL
,	NULL
M.J.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Histological	NULL
grade	NULL
and	NULL
response	NULL
to	NULL
endocrine	NULL
therapy	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Lancet	NULL
,	NULL
ii	NULL
,	NULL
101	NULL
.	NULL

PETO	NULL
,	NULL
R.	NULL
,	NULL
PIKE	NULL
,	NULL
M.C	NULL
.	NULL

,	NULL
ARMITAGE	NULL
,	NULL
P.	NULL
&	NULL
7	NULL
others	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
.	NULL

Design	NULL
and	NULL
analysis	NULL
of	NULL
randomised	NULL
clinical	NULL
trials	NULL
requiring	NULL
prolonged	NULL
observation	NULL
of	NULL
each	NULL
patient	NULL
.	NULL

II	NULL
Analysis	NULL
and	NULL
examples	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
35	NULL
,	NULL
1	NULL
.	NULL

PICHON	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
PALLUD	NULL
,	NULL
C.	NULL
,	NULL
BRUNET	NULL
,	NULL
M.	NULL
&	NULL
MILGROM	NULL
,	NULL
E.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Relationship	NULL
of	NULL
presence	NULL
of	NULL
progesterone	NULL
receptors	NULL
to	NULL
prognosis	NULL
in	NULL
early	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
40	NULL
,	NULL
3357	NULL
.	NULL

RASMUSSEN	NULL
,	NULL
B.B	NULL
.	NULL

,	NULL
ROSE	NULL
,	NULL
C.	NULL
,	NULL
THORPE	NULL
,	NULL
$	NULL
.M	NULL
.	NULL

,	NULL
HOU-JENSEN	NULL
,	NULL
K.	NULL
,	NULL
DAEHNFELDT	NULL
,	NULL
J.L	NULL
&	NULL
PALSHOF	NULL
,	NULL
T.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Histopathological	NULL
-	NULL
characteristics	NULL
-	NULL
and	NULL
-	NULL
oestrogen	NULL
receptor	NULL
content	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Vichows	NULL
Arch	NULL
.	NULL

(	NULL
Pathol	NULL
.	NULL

Anat	NULL
.	NULL
)	NULL

,	NULL
390	NULL
,	NULL
347	NULL
.	NULL

ROLLAND	NULL
,	NULL
P.H	NULL
.	NULL

,	NULL
JACQUEMIER	NULL
,	NULL
J	NULL
.	NULL

&	NULL
MARTIN	NULL
,	NULL
P.M.	NULL
(	NULL
1980	NULL
)	NULL
.	NULL

Histological	NULL
differentiation	NULL
in	NULL
human	NULL
breast	NULL
cancer	NULL
is	NULL
related	NULL
to	NULL
steroid	NULL
receptors	NULL
and	NULL
stromal	NULL
elastosis	NULL
.	NULL

Cancer	NULL
Chemother	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
5	NULL
,	NULL
73	NULL
.	NULL

ROSEN	NULL
,	NULL
P.P	NULL
.	NULL

,	NULL
MENENDEZ-BOTET	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
NISSELBAUM	NULL
,	NULL
J.S	NULL
.	NULL

&	NULL
4	NULL
others	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
.	NULL

Pathological	NULL
review	NULL
of	NULL
breast	NULL
lesions	NULL
analysed	NULL
for	NULL
estrogen	NULL
receptor	NULL
protein	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
35	NULL
,	NULL
3187	NULL
.	NULL

SANDER	NULL
,	NULL
S.	NULL
(	NULL
1968	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
uptake	NULL
of	NULL
oestradiol	NULL
in	NULL
biopsies	NULL
from	NULL
25	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

Acta	NULL
.	NULL

Pathol	NULL
.	NULL

Microbiol	NULL
.	NULL

Scand	NULL
.	NULL

,	NULL
74	NULL
,	NULL
301	NULL
.	NULL

SAMAAN	NULL
,	NULL
NA	NULL
.	NULL

,	NULL
BUZDAR	NULL
,	NULL
A.U	NULL
.	NULL

,	NULL
ALDINGER	NULL
,	NULL
KA	NULL
.	NULL

&	NULL
4	NULL
others	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Estrogen	NULL
receptor	NULL
:	NULL
a	NULL
prognostic	NULL
factor	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
47	NULL
,	NULL
554	NULL
.	NULL

SAY	NULL
,	NULL
C.C	NULL
.	NULL

&	NULL
DONEGAN	NULL
,	NULL
W.L	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
.	NULL

Invasive	NULL
carcinoma	NULL
of	NULL
the	NULL
breast	NULL
:	NULL
Prognostic	NULL
significance	NULL
of	NULL
tumour	NULL
size	NULL
and	NULL
involved	NULL
axillary	NULL
lymph	NULL
nodes	NULL
.	NULL

Cancer	NULL
,	NULL
34	NULL
,	NULL
468	NULL
.	NULL

SCARFF	NULL
,	NULL
R.W	NULL
.	NULL

&	NULL
TORLONI	NULL
,	NULL
H.	NULL
(	NULL
1968	NULL
)	NULL
.	NULL

Histological	NULL
typing	NULL
of	NULL
breast	NULL
tumours	NULL
.	NULL

In	NULL
:	NULL
International	NULL
-	NULL
Histological	NULL
Classification	NULL
of	NULL
Tumours	NULL
No	NULL
.	NULL

2	NULL
,	NULL
p.	NULL
17	NULL
,	NULL
Geneva	NULL
:	NULL
WHO	NULL
.	NULL

SCATCHARD	NULL
,	NULL
G.	NULL
(	NULL
1949	NULL
)	NULL
.	NULL

The	NULL
attraction	NULL
of	NULL
proteins	NULL
for	NULL
small	NULL
molecules	NULL
and	NULL
ions	NULL
.	NULL

Ann	NULL
.	NULL

N.Y.	NULL
Acad	NULL
.	NULL

of	NULL
Science	NULL
,	NULL
51	NULL
,	NULL
660	NULL
.	NULL

SHIVAS	NULL
,	NULL
A.A.	NULL
&	NULL
DOUGLAS	NULL
,	NULL
J.G	NULL
.	NULL

(	NULL
1972	NULL
)	NULL
.	NULL

The	NULL
prognostic	NULL
significance	NULL
of	NULL
elastosis	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

J.	NULL
R.	NULL
Col.	NULL
Surg	NULL
.	NULL

(	NULL
Edin	NULL
.	NULL
)	NULL

17	NULL
,	NULL
315	NULL
.	NULL

SILVESTRINI	NULL
,	NULL
R.	NULL
,	NULL
DAIDONE	NULL
,	NULL
M.G	NULL
.	NULL

&	NULL
DIFRONZO	NULL
,	NULL
G.	NULL
(	NULL
1979	NULL
)	NULL
.	NULL

Relationship	NULL
between	NULL
proliferative	NULL
activity	NULL
and	NULL
estrogen	NULL
receptors	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Cancer	NULL
,	NULL
44	NULL
,	NULL
665	NULL
.	NULL

SKINNER	NULL
,	NULL
LG	NULL
.	NULL

,	NULL
BARNES	NULL
,	NULL
D.M	NULL
.	NULL

&	NULL
RIBEIRO	NULL
,	NULL
G.G	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

The	NULL
clinical	NULL
value	NULL
of	NULL
multiple	NULL
steroid	NULL
receptor	NULL
assay	NULL
in	NULL
breast	NULL
cancer	NULL
management	NULL
.	NULL

Cancer	NULL
,	NULL
46	NULL
,	NULL
2939	NULL
.	NULL

TERENIUS	NULL
,	NULL
L.	NULL
,	NULL
JOHANSSON	NULL
,	NULL
H.	NULL
,	NULL
RIMSTEN	NULL
,	NULL
A	NULL
.	NULL

&	NULL
THOREN	NULL
,	NULL
L.	NULL
(	NULL
1974	NULL
)	NULL
.	NULL

Malignant	NULL
and	NULL
benign	NULL
mammary	NULL
disease	NULL
:	NULL
estrogen	NULL
binding	NULL
in	NULL
relation	NULL
to	NULL
clinical	NULL
data	NULL
.	NULL

Cancer	NULL
,	NULL
33	NULL
,	NULL
1364	NULL
.	NULL

THORESEN	NULL
,	NULL
S.	NULL
,	NULL
TANGEN	NULL
,	NULL
M.	NULL
,	NULL
STA	NULL
,	NULL
K.F	NULL
.	NULL

&	NULL
HARTVEIT	NULL
.	NULL

F.	NULL
(	NULL
1981	NULL
)	NULL
.	NULL

Oestrogen	NULL
receptor	NULL
values	NULL
and	NULL
histological	NULL
grade	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Histopathology	NULL
,	NULL
5	NULL
,	NULL
257	NULL
.	NULL

VON	NULL
MAILLOT	NULL
,	NULL
K.	NULL
,	NULL
HORKE	NULL
,	NULL
W.	NULL
&	NULL
PRESTELE	NULL
,	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
.	NULL

Prognostic	NULL
significance	NULL
of	NULL
the	NULL
steroid	NULL
receptor	NULL
content	NULL
in	NULL
primary	NULL
breast	NULL
cancer	NULL
.	NULL

Arch	NULL
.	NULL

Gynaecol	NULL
.	NULL

,	NULL
231	NULL
,	NULL
185	NULL
.	NULL

WESTERBERG	NULL
,	NULL
H.	NULL
,	NULL
GUSTAFSON	NULL
,	NULL
S.A.	NULL
,	NULL
NORDENSKJOLD	NULL
,	NULL
°	NULL
_	NULL
B.	NULL
,	NULL
SILEVERSWARD	NULL
,	NULL
C.	NULL
&	NULL
WALLGREN	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Estrogen	NULL
receptor	NULL
level	NULL
and	NULL
other	NULL
factors	NULL
in	NULL
early	NULL
recurrence	NULL
of	NULL
breast	NULL
cancer	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
26	NULL
,	NULL
429	NULL
,	NULL
WITTLIFF	NULL
,	NULL
V.L	NULL
.	NULL

,	NULL
HILF	NULL
,	NULL
R.	NULL
,	NULL
BROOKS	NULL
,	NULL
W.F	NULL
.	NULL

,	NULL
SAVLOV	NULL
,	NULL
ED	NULL
.	NULL

,	NULL
HALL	NULL
,	NULL
T.C	NULL
.	NULL

&	NULL
ORLANDO	NULL
,	NULL
R.A.	NULL
(	NULL
1971	NULL
)	NULL
.	NULL

Specific	NULL
estrogen	NULL
binding	NULL
capacity	NULL
of	NULL
the	NULL
cytoplasmic	NULL
receptor	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
breast	NULL
tissues	NULL
in	NULL
humans	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
32	NULL
,	NULL
1983	NULL
.	NULL

